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ABSTRACT
The mechanism of biomineralization is unknown. In bone, it has been proposed that
an acidic phosphoprotein of the extracellular matrix (ECM) is important in the nucleation of
hydroxyapatite (HA). The mineralized tissue protein, bone sialoprotein (BSP), has been
shown to be a potent nucleator of HA and this activity is increased upon binding to type I
collagen. The collagen-binding domain of BSP has been determined to be a highly conserved
region (spanning amino acid residues 18-45); however, the area of collagen involved in this
interaction is unknown.
In this study, a chemical cross-linking method was initially utilized to map the BSPbinding region on collagen. These experiments involved the incubation and interaction of
five different single-cysteine recombinant BSP (1-100) mutants and type I collagen in the
presence of two sulfhydryl-reactive, photoactivatable cross-linking reagents: ρ-azidophenacyl
bromide (APB) and N-[4-(ρ-azidosalicylamido) butyl]-3’-(2’-pyridyldithio) propionamide
(APDP). However, due to the low yield observed from SDS-PAGE in all instances, the
complexes were not further characterized.
As an alternate approach, rotary-shadowing transmission electron microscopy (TEM)
was used. This involved incubation of recombinant BSP (rBSP) with type I collagen, rotaryshadowing with platinum and analysis by TEM. Rotary-shadowing of BSP revealed a 10-nm
globular structure that is linked to a thread-like structure of ~25 nm while type I collagen
appeared as semi-flexible, rod-like structures. Combining BSP and collagen showed a locus
of interaction at a site that averages approximately 31% from the N-terminus, based on the
site of interaction of an antibody to the N-terminus of the collagen molecule. Due to the
observed variability, BSP interacts with collagen between residues 255-375. Based on the
locus of interaction, the arrangement of the collagen fibril, the highly flexible structure of
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BSP and the hydrophobic nature of the BSP-collagen binding interaction, we postulate that
the N-terminal hydrophobic sequence (residues 18-45) of BSP binds collagen in an overlap
region at a site that is rich in hydrophobic residues, while the two glutamic acid-rich regions
extend into the gap region of the adjacent collagen molecule.
Within the collagen-binding domain of BSP, there is a highly conserved thrombincleavage site at Arg27-Tyr28. Thrombin cleaves rat BSP in the middle of the collagenbinding domain (residues 18-45), which effectively abolishes collagen-binding, implying
physiological significance. To address the relevance, incubation of thrombin with BSP and
fibrillar collagen and with demineralized bone chips was performed to determine if BSP was
released from its complexes. Analysis with SDS-PAGE and western blotting demonstrated
that rBSP bound to type I collagen fibrils is susceptible to thrombin cleavage. Similarly,
endogenous BSP present in demineralized bone chips is also released from these chips with
thrombin incubation. Since BSP appears to enhance osteoprogenitor cell migration and
differentiation, this suggests that, upon injury, the release of BSP from bone may provide
signals to initiate the repair process. In summary, the results from these studies are important
in better understanding the BSP-collagen interaction and its role in bone formation and
mineralization.

Keywords bone sialoprotein, phosphoprotein, SIBLING proteins, type I collagen,
biomineralization, hydroxyapatite nucleation, chemical cross-linking, electron microscopy,
protein-collagen interaction, thrombin
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CHAPTER ONE
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1.1

GENERAL INTRODUCTION
Bone is a specialized connective tissue consisting of three main components:

mineral, cells and extracellular matrix (ECM). Bone undergoes constant change through
remodeling,a process involving the resorption of bone and its reformation. Bone has three
primary functions: (1) mechanical support, (2) protection of vital organs, and (3) storage
of calcium and phosphate ions as a reserve which are essential for homeostasis (1, 2).
Within bone, there are three phases: a cellular, organic and inorganic phase.
The cellular phase consists of three different bone cells: osteoblasts, osteoclasts
and osteocytes (3). The organic phase comprises predominantly type I collagen (90%)
and non-collagenous proteins (NCPs) such as osteopontin (OPN) and bone sialoprotein
(BSP). The inorganic phase comprises 65% of the total bone weight and is composed
primarily of hydroxyapatite crystals [HA; Ca10(PO4)6(OH)2] which contribute to the
mechanical rigidity of bone.
Biomineralization is a complex, yet poorly characterized process that involves
many factors. Precise mechanisms of initiation, growth and packing of crystals are
unknown. Several mechanisms for biomineralization have been postulated, including the
proposal that an acidic phosphoprotein present in the ECM of mineralized tissues, when
bound to type I collagen, will induce the nucleation of HA (4). BSP is an acidic noncollagenous phosphoprotein that is expressed primarily in mineralized tissues (5) and has
been shown to be a potent nucleator of HA (6, 7). It is postulated that BSP is secreted into
the ECM by osteoblasts, binds to type I collagen in the gap regions or the regions
adjacent to it, and mediates mineral formation (Figure 1.1).
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A

B

Figure 1.1 Model of BSP-mediated hydroxyapatite nucleation.
(A) The hydroxyapatite crystals (HA) are deposited onto a type I collagen-rich matrix.
The collagen matrix neither promotes nor inhibits HA nucleation, but rather acts as the
scaffold upon which HA crystals are deposited. BSP is a potent nucleator of HA with the
two glutamic acid-rich regions (brown) being responsible for the activity and this
nucleation activity is increased 10-fold when bound to type I collagen. Furthermore, BSP
is postulated to bind to type I collagen (purple) in the gap regions or regions adjacent to it
where early mineral formation is seen to occur. (B) Electron micrograph of calcified
turkey tendon showing initial mineral formation occurring in the gap regions of collagen.
[Adapted from (8)]
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1.2

BONE DEVELOPMENT
The bones of the modern human skeleton are formed by two different processes:

endochondral ossification and intramembranous ossification (9, 10). Long bones of the
body are formed through endochondral ossification while the flat bones form through
intramembranous ossification. Both processes involve condensation of mesenchymal
stem cells (MSCs), differentiation of these cells, secretion of an osteoid (uncalcified bone
matrix) and the initial formation of woven bone that is eventually remodeled to mature
lamellar bone. The main difference between the two bone development processes is the
presence of a cartilaginous intermediate in endochondral ossification (9).

1.2.1 Skeletal Cell Types
1.2.1.1 Osteoblasts
Osteoblasts are derived from MSCs, more specifically, the osteoprogenitor cells
within the periosteum and bone marrow. Differentiation into osteoblasts is induced by
various growth factors such as bone morphogenetic proteins (BMPs) and once
differentiated; these cells display a range of genetic markers including Osterix, alkaline
phosphatase and BSP. Osteoblasts are responsible for synthesizing the osteoid matrix via
the secretion of collagenous and non-collagenous proteins (10).
1.2.1.2 Osteocytes
Osteocytes are the most abundant cells in bone tissue, comprising over 90% (11,
12). These cells are derived from mature osteoblasts that become engulfed in the
mineralized tissue. Osteocytes are interconnected by long cytoplasmic extensions known
as canaliculi and reside in spaces called lacunae (11, 13). These canaliculi function as
routes for nutrients and oxygen transport and exchange. Additionally, osteocytes are
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thought to act as mechanosenors such as for strain/stress and detecting fractures within
the bone, and are crucial to the bone-remodeling process.
1.2.1.2 Osteoclasts
Osteoclast precursors are haematopoietic in origin, arising from the spleen and
bone marrow. Osteoclast precursors are derived from the monocyte/macrophage lineage.
Osteoclasts are multinuclear (containing 10-20 nuclei with 1-2 nucleoli in each nucleus),
and are responsible for bone remodeling in the process known as bone resorption (12).

1.2.2 Intramembranous Ossification
Intramembranous ossification is the process for formation of flat bones, which
include the skull and mandible. A cartilaginous intermediate is not present in this process.
MSCs condense within a highly vascularized area of embryonic tissue and differentiate
directly into pre-osteoblasts and eventually osteoblasts in regions known as ossification
centres. Osteoblasts begin to secrete an osteoid matrix rich in type I collagen.
Calcification traps many of the osteoblasts in the mineralized tissue where they
differentiate into osteocytes. Osteoblasts and osteocytes deposit non-collagenous proteins
and type I collagen aggregate randomly to form woven bone. Most of the woven bone is
eventually remodeled and replaced by mature lamellar bone by clustering type I collagen
fibrils in parallel arrays (9).

1.2.3 Endochondral Ossification
Endochondral ossification is a multi-step process requiring the formation and
degradation of a cartilaginous intermediate that serves as template for the formation of
long bones in the human body (9). MSCs condense, proliferate and differentiate into
chondrocytes all while depositing a cartilaginous ECM comprising of mainly type II
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collagen and cartilage-specific matrix proteins and proteoglycans. The tissue grows
axially following the growth plates present at each end of the forming tissue. This process
continues until the growth plates close at puberty.
In the process of mineralization, chondrocytes mature into hypertrophic
chondrocytes and undergo apoptosis. The hypertrophic chondrocytes express proteins
distinctly different from those expressed by chondrocytes, including collagen type X,
BSP, matrix Gla protein and OPN (14). Following this event, vascular invasion allows
the recruitment of osteoclast precursors from the circulation which then proceed to resorb
the calcified cartilaginous matrix and induce the remodeling of the tissue mediated by
osteoblasts. Osteoblasts synthesize osteoid via secretion of both collagenous and noncollagenous proteins. Following calcification, woven bone is initially formed and is
eventually remodeled and replaced with mature lamellar bone.

1.2.4 Bone Repair
Bone repair occurs through a sequence of four stages: inflammation, soft callus
formation, hard callus formation and remodeling. In response to bone injury, the blood
coagulation cascade is activated to form a haematoma. Over two to three days, the
haematoma is gradually replaced by granulation tissue. Progenitor cells of the periosteum
(membrane of connective tissue that lies the outer surface of bone) nearest the fracture
site differentiate into chondrocytes and synthesize cartilage, while progenitor cells further
away differentiate into osteoblasts and synthesize osteoid. Together, these processes form
the soft callus. Following calcification of the osteoid, a hard callus of woven bone is
formed, while the cartilage becomes hyaline cartilage. Eventually, a union of the fracture
gap occurs and the woven bone is remodeled by osteoclasts and osteoblasts to eventually
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form mature lamellar bone (15). Bone remodeling will continue until the form and
strength of the bone are restored to conditions prior to the fractured state.
If the injury is too severe that natural healing cannot repair the bone fracture, then
surgical procedures may help in the healing process. For example, metal scaffolds
(primarily titanium) are often used to hold the fractured bones in place to facilitate the
bone healing. Additionally, the metal scaffolds may be coated with components that have
been shown to increase bone repair such as HA, type I collagen, BSP or BMP (16).

1.3

BIOMINERALIZATION
Biomineralization refers to the process by which organisms use dissolved ions to

form mineral crystals (17). Biological organisms have been using minerals for over 3.5
billion years and the earliest evidence of this process is the fossil of stromatolites
entrapped in sedimentary rocks. Mineralized skeletal structures first appeared
approximately 540 million years ago (18) and are either comprised of calcium carbonate
or calcium phosphate. Calcium carbonate-based skeletal systems are found primarily in
invertebrates such as molluscs and crustacean, whereas a crystalline form of calcium
phosphate in the form of HA, is found in bones and teeth.
By transmission electron microscopy (TEM), HA crystals found in bone, dentin
and mineralized tendon tend to be plate-like, with average dimensions of ~45 nm in
length, ~25 nm in width and 3-6 nm thick (3, 19). Moreover, the c axes of the HA
crystals are aligned with the collagen fibril axis (20).
Today, biomineralization occurs in all five biological kingdoms resulting in
diverse array of minerals for skeletal, taxis and protective functions (17).
Biomineralization still remains an active area of research as precise mechanisms of
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initiation, growth and packing of crystals are unknown. However, it is believed that this
process is tightly regulated by secreted proteins in the human body, as spontaneous
calcifications are rare in healthy individuals. While there are several postulated
mechanisms for biomineralization, including the involvement of matrix vesicles (21, 22)
and inhibition mechanisms involving the removal of mineralization inhibitors (23-26),
one mechanism to account for bone mineralization that has significant support in the
literature is discussed below.

1.3.1 Organic Matrix-Mediated Mineralization
Organic matrix-mediated biomineralization involves the presence of a surface that
promotes nucleation of crystals (27). The surface chemistry of the organic matrix is
imperative to crystal formation and growth. In regards to the proteins found in the
organic matrix, the surface chemistry is dictated by the primary and secondary structure
and/or post-translational modifications (PTMs) (28). To date, proteins identified to be
mediators of crystal formation and growth are highly acidic and phosphorylated (29).
In organic matrix-mediated biomineralization, there are four steps involved in
crystal formation. The first two steps involve the sequestration and adsorption of Ca2+
and PO43- ions onto an organic matrix leading to the nucleation and formation of
nanometer-sized particles and eventually critical nuclei. The two following steps involve
the stabilization of the critical nuclei and as a result, the formation of HA crystals (27).
In bone, it is proposed by some that mineralization occurs through a process
known as epitactic nucleation where a protein mimics a crystal face resulting in the
formation of a critical nucleus (17). More specifically, the proposed mechanism involves
type I collagen acting as the pre-existing surface upon which the ions are deposited and
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nucleated by acidic proteins (4, 30-32). BSP is an acidic non-collagenous phosphoprotein
that is expressed primarily in mineralized tissues (5) and has been shown to be a potent
nucleator of HA (6, 7, 33). BSP will be discussed in greater detail later in this chapter.

1.4

ORGANIC PHASE
The organic phase of bone comprises 30% of the total bone weight and is

deposited primarily by osteoblasts and to a lesser extent, osteocytes. It is composed
predominantly of type I collagen (90%) and NCPs such as OPN and BSP. Type I
collagen neither promotes nor inhibits HA nucleation, but merely acts as a structural
scaffold upon which HA are deposited. However the NCPs, specifically the SIBLING
proteins (discussed later in this section), are proposed to be important in bone
mineralization.

1.4.1 Type I Collagen
There are more than 29 types of collagen, with type I collagen being the most
abundant in the human body. Dividing into subgroups based on the polymeric structures
assembled, type I collagen belongs to the fibril-forming collagen superfamily, which
includes type II, III, V and XI collagen. Type I collagen is a cationic molecule with an
isoelectric point of 8.3. Type I collagen is found in bone, dentin, skin, tendon, ligaments
and cornea and its expression is primarily restricted to cells that form these tissues
including osteoblasts and fibroblasts (34).
1.4.1.1 Type I Collagen Structure
Type I collagen is comprised of three left-handed polypeptides – two identical α1
chains and one α2 chain. Each polypeptide comprises approximately 1,000 amino acid
residues and is approximately 100 kDa (34, 36, 37). The three polypeptides wind together
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to form a right-handed triple-helical structure with short non-helical telopeptides at both
ends (Figure 1.2A) (37, 38). Therefore, the molecular weight of the full, triple-helical
collagen structure is approximately 300 kDa.
Type I collagen has a characteristic repeating Gly-X-Y sequence, where X is
commonly proline and Y is commonly 4-hydroxyproline. These residues are important in
limiting the rotation of the polypeptide chains (34, 35). The 4-hydroxyproline residue is
also involved in the stabilization of the triple-helix by forming hydrogen bonds and water
bridges (34). The glycine residue at every third amino acid along each chain is crucial for
the formation of the helix turn, since glycine has the smallest side chain and can fit within
the centre of the triple helix, whereas the side chains of all the other amino acids cannot
without disrupting the triple helix (35).
1.4.1.2 Type I Collagen Fibril Formation
Type I collagen monomers, which are approximately 300 nm in length and 1.4 nm
in diameter, spontaneously aggregate forming fibrils resulting in overlap and gap regions
with a periodicity (D) of 67 nm or 234 residues (Figures 1.2A and 1.2B) (37, 39). This
arrangement is referred to as a staggered array or the Hodge and Petruska model (40).
Each overlap region is approximately 27 nm (0.4 D) while each gap region is
approximately 40 nm (0.6 D). In addition, the pore space between adjacent type I
collagen molecules is 0.24 nm. The characteristic banding pattern resulting from the
overlap and gap regions can be observed by negative staining of the collagen fibrils
(Figure 1.2C) (37, 39). Moreover, positive staining of type I collagen fibrils with
phosphotungstic acid (PTA) results in twelve bands within a D-period that are designated
as a1-a4, b1, b2, c1-c3, d, and e1 and e2 (Figures 1.2D and 1.2E). These bands are a result of
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the uptake of PTA anions by positively charged amino acids (i.e. lysine, hydroxylysine,
arginine, and to a lesser extent, histidine) (41, 42). The gap region of the collagen fibril
consists of a3,2,1, e2,1, d and c3 while the overlap region consists of c2,1, b2,1, and a4,3.
Side-to-side intermolecular interactions, rather than end-to-end interactions, are
important in maintaining the integrity of the collagen fibril (39). In addition, the nonhelical telopeptides are important for stabilizing the collagen fibrils by facilitating
intermolecular cross-links (39). Interestingly, early mineral formation has been observed
in the gap regions of collagen fibrils.
There are many proposed models of the 3-D organization of type I collagen,
however; there is one model that has significant support in the literature. Landis et al.,
proposed that the packing of consecutive 2-D collagen arrays into 3-D assemblages
results in the formation of channels or gaps. These channels or gaps (with pore sizes of
0.24 nm) are postulated to be the sites of nucleation (43).
Although the structure of type I collagen is quite complex, the structure is
physiologically relevant. To date, approximately 200 mutations have been characterized
in the two genes, COL1A1, COL1A2, encoding the 2 different α chains of type I
collagen. These mutations result in severe pathological conditions such as osteogenesis
imperfecta (OI) and Ehlers-Danlos syndrome (44).
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Figure 1.2 Type I collagen structure.
(A) Triple-helical type I collagen monomers spontaneously aggregate forming fibrils
which result in (B) overlap and gap regions with a D-periodicity of 67 nm. (C) The
characteristic banding pattern resulting from the overlap and gap regions are observed by
negative staining with sodium phosphotungstic acid (1 %, pH 7). (D) The collagen fibrils
were positively stained with phosphotungstic acid (1 %, pH 3.4) and then uranyl acetate
(1 %, pH 4.2) resulting in (E) twelve staining bands. [Adapted from (45)]
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1.4.1.3 Biosynthesis of Type I Collagen
The fibril-forming collagen family is first synthesized in the endoplasmic
reticulum (ER) as soluble procollagen. They are then converted into collagen molecules
via a series of enzymatic reactions. Proline residues at the Y position of the Gly-X-Y
repeat and lysine residues undergo hydroxylation to 4-hydroxyproline and hydroxylysine
by prolyl-4-hydroxylase and lysyl hydroxyalase (46). Some of the proline residues at the
X position are converted to 3-hydroxyproline by prolyl-3-hydroxylase. In terms of the
hydroxylysine residues, galactose or both galactose and glucose are added to selected
residues. Once the C-terminal propeptides associate and form intrachain and interchain
disulfide bonds, the triple-helical conformation starts to assemble and propagate toward
the N-terminus in a zipper-like manner.
Following or during secretion into the ECM, cleavage of N - and C- propeptides
by procollagen N- and C- proteinases allows for the self-assembly of collagen monomers
into collagen fibrils (37, 47). Furthermore, to stabilize the collagen fibrils, the enzyme
lysyl oxidase converts selected lysine and hydroxylysine residues (found in the nonhelical telopeptides) to aldehyde derivatives leading to cross-link formation.

1.4.2 The SIBLING Protein Family
The ECM contains many non-collagenous proteins including the SIBLING (Small
Integrin-Binding LIgand, N-linked Glycoprotein) protein family (48, 49). Members of the
SIBLING protein family include: OPN, dentin matrix protein 1 (DMP-1), dentin
sialophosphoprotein [DSPP – under physiological conditions, DSPP is cleaved by PHEX
forming dentin sialoprotein (DSP) and dentin phosphophoryn (DPP)], matrix
extracellular phosphoglycoprotein (MEPE) and bone sialoprotein (BSP) (48, 50).
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The SIBLING proteins are expressed predominantly in mineralized tissues and
are proposed to have important roles in mineralization. In bone and dentin, BSP and OPN
exist as full-length forms, whereas DMP-1 and DSPP exist as distinct proteolytic-derived
large peptides. The SIBLING proteins share many features such as gene location and
structural characteristics (48, 50). The genes encoding the SIBLING proteins are all
located within a 375,000 bp region on chromosome 4q21 (human) and display similar
exon structures (50). It is likely that the SIBLING genes arose by gene duplication and
divergence (49). Structural characteristics shared among the SIBLING proteins include
the presence of an Arg-Gly-Asp (RGD) site which is important in cell-integrin binding,
PTMs such as phosphorylation and glycosylation and high levels of acidic amino acids
(51).
1.4.2.1 SIBLING Structure
Members of the SIBLING family possess a loose, flexible structure and this lack
of structure has been postulated to be important for interacting with numerous binding
partners including collagen, integrins and HA (49). NMR studies of OPN (49) and DPP
(52) reveal the proteins to adopt a random coil conformation. Based on secondarystructure prediction programs, circular dichroism (CD) (53) and small-angle X-ray
scattering (54), DMP-1 has also been shown to possess a random coil secondary
structure. Of relevance, secondary structure programs predict MEPE to be an
unstructured protein (55). Finally, BSP has been shown to be unstructured as will be
discussed in greater detail later in this chapter.
1.4.2.2 Post-Translational Modifications of SIBLING Proteins
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The SIBLING proteins are heavily modified by PTMs such as glycosylations and
phosphorylations. Phosphorylations occur on serine, threonine and to a lesser extent,
tyrosine residues. The kinases postulated to be responsible for phosphorylation are Golgi
casein kinase (gCK), protein kinases (CK1 and CK2) and FAM20 (56). MS analysis of
rat bone-extracted OPN show an average of 10 phosphate groups per molecule (57). DSP
has between 6 to 10 phosphate groups (58) while DPP (comprising approximately 450
amino acid residues) is heavily phosphorylated with an average of 209 phosphates (59).
The SIBLING protein DMP-1 exists as 37-kDa and 57-kDa peptides based on relative
mobility on SDS-PAGE, containing 12 and 41 phosphates, respectively (60).
Phosphorylation has been demonstrated to have a significant impact on the SIBLING
proteins’ ability to modulate mineral formation. For example, phosphorylation of OPN is
required for HA inhibition (57) while the phosphorylation of the 57 kDa fragment of
DMP-1 alters its function from being a HA inhibitor to a HA nucleator (60). In dentin,
Torres-Quintana et al. found that mineralization was decreased in the presence of kinase
inhibitors, demonstrating the importance of these phosphorylations (61).
The SIBLING proteins also contain variable levels of glycosylation (e.g., rat
bone-extracted OPN has four O-linked oligosaccharides); however, their precise
functions are unknown.
1.4.2.3 SIBLING Function
The SIBLING proteins BSP, DMP-1 and DPP are thought to be HA nucleators
whereas OPN and MEPE are thought to be inhibitors of HA. These proteins are
expressed predominantly in mineralized tissues and are proposed to be important in
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mineralization. Knock-out models of the various SIBLING proteins have been generated
and all display abnormalities in bone and/or tooth formation.
At the early stages in life, there are observable bone phenotypes in BSP-deficient
mice. At 0-4 months, the mice show decreased mineralization of cortical bones and
shortened long bones, suggesting BSP is important in early mineral formation. DSPP-null
mice displayed extensive tooth abnormalities similar to dentinogenesis imperfecta type
III, a condition characterized by enlarged pulp chambers, increased width of predentin
zone, hypomineralization and pulp exposure (62). Skeletal abnormalities such as enlarged
growth plates, as well as dentin wall hypomineralization, are evident in DMP-1 knockout mice (63, 64). Increased mineral content and bone mass are present in OPN-deficient
and MEPE-deficient mice. Collectively, these findings demonstrate the physiological
importance of the SIBLING proteins for proper bone and tooth formation (23, 65).

1.4.3 Bone Sialoprotein
Bone sialoprotein (BSP) is an acidic non-collagenous phosphoprotein and a
member of the SIBLING protein family. This acidic protein was first isolated as 25 kDa
fragments from the cortical bone of cow by Herring in 1963 (66). However, due to
difficulties in extracting the protein, it was not until 1983 that intact BSP was purified
from fetal calf bone by Fisher et al., (67). BSP has also been isolated from pig (68), rat
(69), human (70), rabbit (71) and chicken (72) (Figure 1.3). More recently, a BSP-like
protein has been identified in amphibian (African clawed toad) and reptile (caiman)
species (73).
Mammalian BSP contains approximately 327 amino acid residues, 16 of which
are the signal peptide (Figure 1.3). BSP contains the following functional domains: a
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hydrophobic region near the N-terminus (spanning residues 18-45) shown to bind to type
I collagen (74) two glutamic acid-rich regions located in the middle of the molecule,
which are responsible for HA binding and nucleation and a C-terminal RGD cell-binding
motif (75). Of relevance, there is a highly conserved thrombin-cleavage site at Arg27Tyr28 within the type I collagen binding region (unpublished data).
Analysis of the deduced amino acid sequences of BSP from different mammalian
species shows a high level of conservation. Moreover, identity of up to 90% is observed
within specific domains (i.e., the two glutamic acid-rich regions, the RGD motif and the
collagen-binding domain) (74, 76). The high level of conservation of these domains
among species implies preservation of function (Figure 1.4).
1.4.3.1 Secondary Structure of Bone Sialoprotein
BSP has been shown by NMR (49, 77), CD spectroscopy (6, 78) and small angle
X-ray scattering (6) to possess a loose, flexible structure. Furthermore, after rotaryshadowing TEM, BSP appears as a monomer possessing a ~10 nm globular structure
linked to an elongated thread-like structure (~25 nm) (78). Similar to other SIBLING
proteins, it has been hypothesized that this lack of order allows BSP to simultaneously
interact with proteins such as type I collagen (49).
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Figure 1.3. Schematic of BSP functional domains.
BSP contains the following functional domains: type I collagen-binding region (residues
18-45), two glutamic acid-rich regions (which are important for HA binding and
nucleation) and a RGD cell-binding motif. Within the type I collagen binding region,
there is a thrombin cleavage site at Arg27-Tyr28 (insert). Post-translational modifications
such as N- and O- linked glycosylations, phosphorylations and tyrosine sulfations are
shown.
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Figure 1.4 Sequence alignments for mammalian bone sialoprotein.
The amino-acid sequences were aligned to generate a consensus sequence. Residues that
are identical in five of the six sequences are indicated by upper case letters in the
consensus sequence, whereas residues identical in three or more sequences are indicated
by lower case letters. Residues that are conserved in fewer than three sequences are
indicated by a period. [Adapted from (76)]
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1.4.3.2 Post-Translational Modifications of Bone Sialoprotein
BSP is heavily modified by PTMs which account for up to 30% of the molecular
weight of native BSP. PTMs include N- and O- linked glycosylations, phosphorylations,
tyrosine sulfations and transglutaminase cross-linking. In the absence of PTMs, BSP has
a molecular weight of approximately 33-34 kDa (calculated from the amino acid
sequence). However, as a result of the heterogeneity in PTMs that BSP undergoes, the
molecular weight of individual BSP molecules is highly variable. Based on two separate
MS studies of human bone-derived BSP, the mean mass was determined to be ~52.5 kDa
(79) and ~49 kDa (80). In both studies, a broad peak width (~20 kDa) was observed in
the mass spectrum, reflecting the heterogeneity in PTMs. Of relevance, based on SDSPAGE, native BSP has an apparent molecular weight of 60-80 kDa.
To date, two sulfated tyrosine residues near the RGD sequence (Tyr 259 or 263
and Tyr 297 or 298) have been identified (79). Although it was initially hypothesized that
these residues may modulate cell-attachment capabilities, Midura et al., found that both
bone-extracted and rBSP (unmodified BSP) have comparable cell attachment capabilities
(81). Moreover, blocking of sulfation with chlorate treatment did not alter cell attachment
capabilities of bone-extracted BSP.
The mammalian BSP sequence has three putative sites for N-linked glycosylation
(Asn-X-Ser/Thr) located in the middle of the protein, two of which are conserved across
all mammalian species (82). In addition, there is a fourth putative site for N-linked
glycosylation in human BSP near the N-terminus (83). Matrix-assisted laser desorption
mass spectrometry (MALDI-TOF MS) analysis of human bone-derived BSP has revealed
2 N-linked oligosaccharides (Asn 161 and Asn 166) and 11 O-linked oligosaccharides
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(Ser 92, 214 and 232 and Thr 95, 165, 167, 213, 214, 223, 230, 231 and 232) (84). In
human bone-extracted BSP, Wutkke et al., identified only 8 of the 11 O-linked
oligosaccharides and 4 N-linked oligosaccharides. Collectively, these studies demonstrate
that glycosylation tends to be heterogeneous in both the level and sites of modification.
Although the role of these glycosylations on BSP remains unclear, these modifications
have no apparent affect on collagen-binding activity (74).
Similar to other SIBLING proteins, BSP is highly phosphorylated, particularly at
serine and threonine residues. The mammalian BSP sequence has 5 putative serine
phosphorylation sites for protein kinase C, 9-11 putative Ser/Thr phosphorylation sites
for casein kinase II and 1-2 putative Tyr sites potentially for tyrosine kinase (76). A
number of studies have been devoted to determining the quantity and location of the
phosphorylation sites of BSP in vitro and in vivo (84-87). Findings from these studies
demonstrate the heterogeneity of phosphorylations on BSP. Although phosphorylations
on BSP have no apparent affect on collagen-binding activity (74), these phosphate groups
are important in the modulation of mineral formation and this will be discussed below
1.4.3.3 Tissue Expression of Bone Sialoprotein
BSP expression is primarily restricted to mineralized tissues such as bone, dentin,
cementum, enamel and mineralizing cartilage (5, 83, 88-91). However, other studies have
described BSP to be present in non-mineralized areas such as trophoblastic cells of the
placenta (5, 92), salivary glands (93) and platelets (94). Transcript levels for BSP are
higher in newly formed bone and cementum than in other tissues (95, 96). However,
maximal levels of BSP transcripts and expression are seen during embryonic bone
formation. BSP has been shown to be concentrated at the mineralization front and cement
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lines (boundary of an osteon) (97). Interestingly, by immunogold labeling, BSP has been
shown to be associated with collagen fibres in mineralized tissues (98).
In pathological conditions, BSP is positively correlated with cancers that
metastasize to bone such as breast (99, 100) and prostate cancers (101, 102). In addition,
BSP has been shown to be associated with a 97 kDa protein produced by Staphylococcus
aureus, a bacterium that infects bones and joints (103).
1.4.3.4 Functions of Bone Sialoprotein
BSP is implicated in a variety of physiological functions including cell attachment
and signaling, HA binding and nucleation and type I collagen binding (76).
BSP has a highly conserved RGD site important for cell/integrin binding. The
RGD site interacts with the αvβ3 integrin, a cell-surface receptor present in osteoclasts
(104) and osteoblasts (105). The RGD sequence has significant function because when it
is mutated to KAE, the cell/integrin binding of osteoblasts (106), chondrocytes (107) and
fibroblasts (105, 108) is abolished. Binding of BSP to osteoblasts promotes osteoblast
differentiation and mineralized nodule formation (109, 110), while binding of BSP to
osteoclast progenitor cells appears to be involved in osteoclast generation (111, 112).
BSP is a potent nucleator of HA crystals in agarose (33), gelatin (113) and
collagen gels (114). There is a strong interaction between BSP and HA with the KD of
approximately 0.85 µM (115). The two glutamic acid-rich regions (with contiguous
glutamic acid residues) of BSP are essentially responsible for the nucleation activity (6,
116). Both bone-extracted BSP and prokaryotic-expressed recombinant BSP (rBSP)
lacking PTMs were capable of nucleating HA; however, rBSP was much less potent
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(100-fold decrease in nucleation potency) (6). This indicates that PTMs are not essential,
but aid in nucleation.
Initially, it was believed that electrostatic interactions were responsible for BSP
binding to collagen since type I collagen has a slightly positive charge at neutral pH (98).
However, our previous work demonstrated electrostatic interactions are only partly
involved in the BSP-type I collagen interaction as binding to collagen was reduced, but
not abolished, by the addition of cations, increase in ionic strength or decrease in pH (74).
The BSP-collagen interaction is primarily hydrophobic in nature, as the majority of
collagen-bound BSP was eluted by acetonitrile (114). Bone-extracted BSP and rBSP
(unmodified BSP) bound to type I collagen with approximately equal affinity, KD = 12.1
nM and KD =14.2 nM, implying PTMs are not critical for binding.
Using a solid-phase binding assay and synthetic peptides, the type I collagenbinding site and the structural aspects of collagen involved in its interaction with BSP
were determined. The collagen-binding region on BSP was mapped to residues 18-45, a
region rich in hydrophobic and basic amino acids and highly-conserved among species
(74). Interestingly, previous studies from our laboratory have shown that thrombin
cleaves rat BSP at Arg27-Tyr28, and abolishes collagen binding (114, 117). Moreover,
BSP (114) displayed comparable binding affinities to monomeric and fibrillar type I
collagen (KD = 13 nM), but not to heat-denatured collagen (gelatin) with a binding
affinity (KD) of 44 nM. However, the non-helical telopeptides are not involved in BSPcollagen interaction as pepsin treatment of collagen had no apparent effect. These
findings suggest the BSP-type I collagen interaction requires a native triple-helical type I
collagen structure, but does not require either collagen telopeptides or fibrils (114).
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1.4.3.5 Binding of ECM Proteins to Type I Collagen
A number of ECM proteins other than BSP have been shown to bind to type I
collagen. OPN binds type I collagen at a highly conserved region containing hydrophobic
and acidic amino acid residues (118). The collagen-binding domain of DMP-1 has been
identified to be two acidic-amino-acid-rich regions found at the C-terminal end of the
protein and has a dissociation constant of 3.8 ±1.7 µM (119). A significant decrease in
binding due to substitution of these acidic domains with neutral amino acids suggests that
the interaction between DMP-1 and type I collagen is electrostatic in nature (119). By
EM, DPP has been shown to bind primarily to the fibril surface at the “e” band, which is
in the middle of the gap region (120). Using rotary-shadowing TEM, the DPP binding
location on type I collagen has been mapped to approximately 210 nm from the Nterminal end of the collagen molecule. This binding region corresponds to DPP covering
residues 698 to 750, a region corresponding to an overlap region of the collagen fibril
rather than a gap region (121).

1.5

PURPOSE OF THE THESIS
The mechanism of biomineralization is currently unknown. In bone, it has been

proposed that an acidic phosphoprotein of the ECM, when bound to type I collagen, will
induce the nucleation of HA. BSP is an acidic non-collagenous phosphoprotein that is
expressed primarily in mineralized tissues and has been shown to be a potent nucleator of
HA (6, 7). BSP is secreted into the ECM by osteoblasts, where it is hypothesized that it
binds to type I collagen in the gap regions or the regions adjacent to it where early
mineral formation occur. The collagen-binding region on BSP, rich in only hydrophobic
and basic amino acids, spans residues 18-45, and is highly conserved among species.
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However, the BSP-binding region on type I collagen is unknown. The first objective of
this thesis is to determine the BSP-binding region on type I collagen using a chemical
cross-linking method and rotary-shadowing TEM. These methods will be discussed in
greater detail in the next chapters.
Within the collagen-binding region, there is a highly conserved thrombin cleavage
site at Arg27-Tyr28 and, upon cleavage, collagen-binding is abolished. The physiological
relevance of this conserved thrombin-cleavage site has, however, not been fully
elucidated. In addition to HA nucleation, BSP has been demonstrated to function as a
signaling molecule in physiological pathways. BSP contains a highly-conserved Cterminal RGD site that interacts with the αvβ3 integrin and has been shown to be
important in cell adhesion and migration of osteoblast and tumour cells. Since BSP has
been shown to be a chemotactic agent, we hypothesize that upon bone injury, thrombin
becomes activated, then cleaves and releases BSP into the ECM. Subsequently, BSP can
act as a signaling molecule to recruit osteoprogenitor cells, which will differentiate into
osteoblasts. The second objective of this thesis is to determine whether thrombin cleaves
and releases BSP from type I collagen. The thrombin digestion reactions will be analyzed
using SDS-PAGE, western blotting and MALDI-MS.
Collectively, the results from these studies are important in understanding the
initial stages of bone mineralization which may ultimately lead to the generation of
therapeutic agents to promote bone repair.

26

1.6

REFERENCES

1. Cohen, M.M., Jr. (2006) The new bone biology: pathologic, molecular, and clinical
correlates. Am. J. Med. Genet. A. 140, 2646-2706
2. Weiner, S., and Wagner, H.D. (1998) The material bone: structure-mechanical function
relations. Annu. Rev. Mater. Sci. 28, 271-298
3. Robinson, R.A. (1992) An electron-microscopic study of the crystalline inorganic
component of bone and its relationship to the organic matrix. J. Bone Joint Surg. Am. 34,
389-476
4. Veis, A., and Perry, A. (1967) The phosphoprotein of the dentin matrix. Biochemistry
(N.Y.). 6, 2409-2416
5. Bianco, P., Fisher, L.W., Young, M.F., Termine, J.D., and Robey, P.G. (1991)
Expression of bone sialoprotein (BSP) in developing human tissues. Calcif. Tissue Int.
49, 421-426
6. Tye, C.E., Rattray, K.R., Warner, K.J., Gordon, J.A., Sodek, J., Hunter, G.K., and
Goldberg, H.A. (2003) Delineation of the hydroxyapatite-nucleating domains of bone
sialoprotein. J. Biol. Chem. 278, 7949-7955
7. Hunter, G.K., Hauschka, P.V., Poole, A.R., Rosenberg, L.C., and Goldberg, H.A.
(1996) Nucleation and inhibition of hydroxyapatite formation by mineralized tissue
proteins. Biochem. J. 317, 59-64
8. Arsenault, A.L. (1988) Crystal-collagen relationships in calcified turkey leg tendons
visualized by selected-area dark field electron microscopy. Calcif. Tissue Int. 43, 202-212
9. Provot, S., and Schipani, E. (2005) Molecular mechanisms of endochondral bone
development. Biochem. Biophys. Res. Commun. 328, 658-665

27

10. Shapiro, F. (2008) Bone development and its relation to fracture repair. The role of
mesenchymal osteoblasts and surface osteoblasts. Eur. Cell Mater. 15, 53-76
11. Hongo, H., Hasegawa, T., Sasaki, M., Suzuki, R., Masuki, H., Yamada, T., Shimoji,
S., Kawanami, M., Yamamoto, T., and Amizuka, N. (2012) Bone-Orchestrating Cells,
Hokkaido J. Dent. Sci. 32, 93-103
12. Boyce, B.F., Yao, Z., and Xing, L. (2009) Osteoclasts have multiple roles in bone in
addition to bone resorption. Crit. Rev. Eukaryot. Gene Expr. 19, 171-180
13. Bonewald, L.F. (2011) The amazing osteocyte. J. Bone Miner. Res. 26, 229-238
14. Lefebvre, V., Garofalo, S., and de Crombrugghe, B. (1995) Type X collagen gene
expression in mouse chondrocytes immortalized by a temperature-sensitive simian virus
40 large tumor antigen. J. Cell Biol. 128, 239-245
15. Carano, R.A., and Filvaroff, E.H. (2003) Angiogenesis and bone repair. Drug Discov.
Today. 8, 980-989
16. Samartzis, D., Khanna, N., Shen, F.H., and An, H.S. (2005) Update on Bone
Morphogenetic Proteins and Their Application in Spine Surgery. J Am. Coll. Surg. 200,
236-248
17. Lowenstam, H.H.A., and Weiner, S. (1989) On biomineralization, Oxford University
Press on Demand, New York
18. Addadi, L., and Weiner, S. (1992) Control and design principles in biological
mineralization. Angewandte Chemie. 31, 153-169
19. Weiner, S., and Price, P.A. (1986) Disaggregation of bone into crystals. Calcif. Tissue
Int. 39, 365-375
20. Glimcher, M.J. (1959) Molecular biology of mineralized tissues with particular
reference to bone. Rev. Mod. Phys. 31, 359-393

28

21. Ali, S. (1976) Analysis of matrix vesicles and their role in the calcification of
epiphyseal cartilage. Fed. Proc. 35, 135-142
22. Anderson, H.C. (1969) Vesicles associated with calcification in the matrix of
epiphyseal cartilage. J. Cell Biol. 41, 59-72
23. Boskey, A., Spevak, L., Paschalis, E., Doty, S., and McKee, M. (2002) Osteopontin
deficiency increases mineral content and mineral crystallinity in mouse bone. Calcif.
Tissue Int. 71, 145-154
24. Price, P.A., Toroian, D., and Lim, J.E. (2009) Mineralization by inhibitor exclusion:
the calcification of collagen with fetuin. J. Biol. Chem. 284, 17092-17101
25. Terkeltaub, R.A. (2001) Inorganic pyrophosphate generation and disposition in
pathophysiology. Am. J. Physiol. 281, C1-C11
26. Omelon, S.J., and Grynpas, M.D. (2008) Relationships between polyphosphate
chemistry, biochemistry and apatite biomineralization. Chem. Rev. 108, 4694-4715
27. Cuisinier, F., Steuer, P., Brisson, A., and Voegel, J. (1995) High resolution electron
microscopy study of crystal growth mechanisms in chicken bone composites. J. Cryst.
Growth. 156, 443-453
28. Posner, A., and Betts, F. (1981) Molecular control of tissue mineralization. Chemistry
and Biology of Mineralized Connective tissues: Amsterdam, Elsevier. 257-266
29. George, A., and Veis, A. (2008) Phosphorylated proteins and control over apatite
nucleation, crystal growth, and inhibition. Chem. Rev. 108, 4670-4693
30. Glimcher, M.J., Hodge, A.J., and Schmitt, F.O. (1957) Macromolecular aggregation
states in relation to mineralization: the collagen-hydroxyapatite system as studied in vitro.
Proc. Natl. Acad. Sci.. 43, 860-867
31. Glimcher, M.J. (1989) Mechanism of calcification: role of collagen fibrils and
collagen‐phosphoprotein complexes in vitro and in vivo. Anat. Rec. 224, 139-153

29

32. Hunter, G.K., Nyburg, S.C., and Pritzker, K.P. (1986) Hydroxyapatite formation in
collagen, gelatin, and agarose gels. Coll. Relat. Res. 6, 229-238
33. Hunter, G.K., and Goldberg, H.A. (1993) Nucleation of hydroxyapatite by bone
sialoprotein. Proc. Nat. Acad. Sci. 90, 8562-8565
34. Prockop, D.J., and Kivirikko, K.I. (1995) Collagens: molecular biology, diseases, and
potentials for therapy. Annu. Rev. Biochem. 64, 403-434
35. Ramshaw, J.A., Shah, N.K., and Brodsky, B. (1998) Gly-X-Y tripeptide frequencies
in collagen: a context for host-guest triple-helical peptides. J. Struct. Biol. 122, 86-91
36. Petruska, J.A., and Hodge, A.J. (1964) A subunit model for the tropocollagen
macromolecule. Proc. Natl. Acad. Sci. 51, 871-876
37. Kadler, K.E., Holmes, D.F., Trotter, J.A., and Chapman, J.A. (1996) Collagen fibril
formation. Biochem. J. 316, 1-11
38. Traub, W., and Piez, K.A. (1971) The chemistry and structure of collagen. Adv.
Protein Chem. 25, 243-352
39. Veis, A. (1997) Collagen fibrillar structure in mineralized and nonmineralized tissues.
Curr. Opin. Sol. State Phys. 2, 370-378
40. Petruska, J.A., and Hodge, A.J. (1964) A subunit model for the tropocollagen
macromolecule. Proc. Natl. Acad. Sci. 51, 871
41. Hodge, A.J., and Schmitt, F.O. (1960) The charge profile of the tropocollagen
macromolecule and the packing arrangement in native-type collagen fibrils. Proc. Natl.
Acad .Sci. 46, 186-197
42. Chapman, J.A. (1974) The staining pattern of collagen fibrils: I. An analysis of
electron micrographs. Connect. Tissue Res. 2, 137-150
43. Landis, W.J., and Jacquet, R. (2013) Association of Calcium and Phosphate Ions with
Collagen in the Mineralization of Vertebrate Tissues. Calcif. Tissue Int. 4, 329-337

30

44. Vuorio, E., and De Crombrugghe, B. (1990) The family of collagen genes. Annu. Rev.
Biochem. 59, 837-872
45. Chapman, J.A., and Hulmes, D.J. (1984) Electron microscopy of the collagen fibril.
Martinus Nijhoff Publishers. 1-33
46. Pihlajaniemi, T., Myllylä, R., and Kivirikko, K.I. (1991) Prolyl 4-hydroxylase and its
role in collagen synthesis. J. Hepatol. 13, S2-S7
47. Kadler, K.E., Baldock, C., Bella, J., and Boot-Handford, R.P. (2007) Collagens at a
glance. J. Cell. Sci. 120, 1955-1958
48. Bellahcène, A., Castronovo, V., Ogbureke, K.U., Fisher, L.W., and Fedarko, N.S.
(2008) Small integrin-binding ligand N-linked glycoproteins (SIBLINGs):
multifunctional proteins in cancer. Nat. Rev. Cancer 8, 212-226
49. Fisher, L., Torchia, D., Fohr, B., Young, M., and Fedarko, N. (2001) Flexible
structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem. Biophys.
Res. Commun. 280, 460-465
50. Fisher, L.W., and Fedarko, N.S. (2003) Six genes expressed in bones and teeth
encode the current members of the SIBLING family of proteins. Connect. Tissue Res. 44,
33-40
51. Qin, C., Baba, O., and Butler, W. (2004) Post-translational modifications of sibling
proteins and their roles in osteogenesis and dentinogenesis. Crit. Rev. Oral Biol. Med. 15,
126-136
52. Cross, K.J., Huq, N.L., and Reynolds, E.C. (2005) Protein dynamics of bovine dentin
phosphophoryn. J. Pept. Res. 66, 59-67
53. He, G., Dahl, T., Veis, A., and George, A. (2003) Dentin matrix protein 1 initiates
hydroxyapatite formation in vitro. Connect. Tissue Res. 44 Suppl 1, 240-245

31

54. He, G., Gajjeraman, S., Schultz, D., Cookson, D., Qin, C., Butler, W.T., Hao, J., and
George, A. (2005) Spatially and temporally controlled biomineralization is facilitated by
interaction between self-assembled dentin matrix protein 1 and calcium phosphate nuclei
in solution. Biochemistry 44, 16140-16148
55. Bardet, C., Delgado, S., and Sire, J. (2010) MEPE evolution in mammals reveals
regions and residues of prime functional importance. Cell. Mol. Life Sci. 67, 305-320
56. Tagliabracci, V.S., Xiao, J., and Dixon, J.E. (2013) Phosphorylation of substrates
destined for secretion by the Fam20 kinases. Biochem. Soc. Trans. 41, 1061-1065
57. Keykhosravani, M., Doherty-Kirby, A., Zhang, C., Brewer, D., Goldberg, H.A.,
Hunter, G.K., and Lajoie, G. (2005) Comprehensive identification of post-translational
modifications of rat bone osteopontin by mass spectrometry. Biochemistry 44, 6990-7003
58. Stetler-Stevenson, W.G., and Veis, A. (1983) Bovine dentin phosphophoryn:
composition and molecular weight. Biochemistry 22, 4326-4335
59. Huq, N.L., Cross, K.J., Talbo, G.H., Riley, P.F., Loganathan, A., Crossley, M.A.,
Perich, J.W., and Reynolds, E.C. (2000) N-terminal sequence analysis of bovine dentin
phosphophoryn after conversion of phosphoseryl to S-propylcysteinyl residues. J. Dent.
Res. 79, 1914-1919
60. Tartaix, P.H., Doulaverakis, M., George, A., Fisher, L.W., Butler, W.T., Qin, C.,
Salih, E., Tan, M., Fujimoto, Y., Spevak, L., and Boskey, A.L. (2004) In vitro effects of
dentin matrix protein-1 on hydroxyapatite formation provide insights into in vivo
functions. J. Biol. Chem. 279, 18115-18120
61. Torres-Quintana, M.A., Lécolle, S., and Goldberg, M. (1998) Effects of inositol
hexasulphate, a casein kinase inhibitor, on dentine phosphorylated proteins in organ
culture of mouse tooth germs. Arch. Oral Biol. 43, 597-610
62. Sreenath, T., Thyagarajan, T., Hall, B., Longenecker, G., D'Souza, R., Hong, S.,
Wright, J.T., MacDougall, M., Sauk, J., and Kulkarni, A.B. (2003) Dentin
sialophosphoprotein knockout mouse teeth display widened predentin zone and develop

32

defective dentin mineralization similar to human dentinogenesis imperfecta type III. J.
Biol. Chem. 278, 24874-24880
63. Ling, Y., Rios, H.F., Myers, E.R., Lu, Y., Feng, J.Q., and Boskey, A.L. (2005) DMP1
depletion decreases bone mineralization in vivo: an FTIR imaging analysis. J. Bone
Miner. Res. 20, 2169-2177
64. Feng, J., Huang, H., Lu, Y., Ye, L., Xie, Y., Tsutsui, T., Kunieda, T., Castranio, T.,
Scott, G., and Bonewald, L. (2003) The Dentin matrix protein 1 (Dmp1) is specifically
expressed in mineralized, but not soft, tissues during development. J. Dent. Res. 82, 776780
65. Gowen, L.C., Petersen, D.N., Mansolf, A.L., Qi, H., Stock, J.L., Tkalcevic, G.T.,
Simmons, H.A., Crawford, D.T., Chidsey-Frink, K.L., and Ke, H.Z. (2003) Targeted
disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone
formation and bone mass. J. Biol. Chem. 278, 1998-2007
66. Herring, G.M., and Kent, P.W. (1963) Some Studies on Mucosubstances of Bovine
Cortical Bone. Biochem. J. 89, 405-414
67. Fisher, L.W., Whitson, S., Avioli, L., and Termine, J. (1983) Matrix sialoprotein of
developing bone. J. Biol. Chem. 258, 12723-12727
68. Zhang, Q., Domenicucci, C., Goldberg, H., Wrana, J., and Sodek, J. (1990)
Characterization of fetal porcine bone sialoproteins, secreted phosphoprotein I (SPPI,
osteopontin), bone sialoprotein, and a 23-kDa glycoprotein. Demonstration that the 23kDa glycoprotein is derived from the carboxyl terminus of SPPI. J. Biol. Chem. 265,
7583-7589
69. Gorski, J.P., and Shimizu, K. (1988) Isolation of new phosphorylated glycoprotein
from mineralized phase of bone that exhibits limited homology to adhesive protein
osteopontin. J. Biol. Chem. 263, 15938-15945
70. Fisher, L.W., Hawkins, G.R., Tuross, N., and Termine, J.D. (1987) Purification and
partial characterization of small proteoglycans I and II, bone sialoproteins I and II, and

33

osteonectin from the mineral compartment of developing human bone. J. Biol. Chem.
262, 9702-9708
71. Kinne, R.W., and Fisher, L.W. (1987) Keratan sulfate proteoglycan in rabbit compact
bone is bone sialoprotein II. J. Biol. Chem. 262, 10206-10211
72. Yang, R., Gotoh, Y., Moore, M.A., Rafidi, K., and Gerstenfeld, L.C. (1995)
Characterization of an avian bone sialoprotein (BSP) cDNA: comparisons to mammalian
BSP and identification of conserved structural domains. J. Bone Miner. Res. 10, 632-640
73. Shintani, S., Kamakura, N., Kobata, M., Toyosawa, S., Onishi, T., Sato, A.,
Kawasaki, K., Weiss, K.M., and Ooshima, T. (2008) Identification and characterization
of integrin-binding sialoprotein (IBSP) genes in reptile and amphibian. Gene 424, 11-17
74. Tye, C.E., Hunter, G.K., and Goldberg, H.A. (2005) Identification of the type I
collagen-binding domain of bone sialoprotein and characterization of the mechanism of
interaction. J. Biol. Chem. 280, 13487-13492
75. Goldberg H.A. and Hunter, G.K. (2012) ‘Functional Domains of Bone Sialoprotein’
in Phosphorylated Extracellular Matrix Proteins of Bone and Dentin. (ed. M Goldberg)
Bentham Science Publishers. 2, 256-272
76. Ganss, B., Kim, R.H., and Sodek, J. (1999) Bone sialoprotein. Crit. Rev. Oral Biol.
Med. 10, 79-98
77. Stubbs, J.T., Mintz, K.P., Eanes, E.D., Torchia, D.A., and Fisher, L.W. (1997)
Characterization of Native and Recombinant Bone Sialoprotein: Delineation of the
Mineral‐Binding and Cell Adhesion Domains and Structural Analysis of the RGD
Domain. J. Bone Miner. Res. 12, 1210-1222
78. Wuttke, M., Muller, S., Nitsche, D.P., Paulsson, M., Hanisch, F.G., and Maurer, P.
(2001) Structural characterization of human recombinant and bone-derived bone
sialoprotein. Functional implications for cell attachment and hydroxyapatite binding. J.
Biol. Chem. 276, 36839-36848

34

79. Zaia, J., Boynton, R., Heinegård, D., and Barry, F. (2001) Post-translational
modifications to human bone sialoprotein determined by mass spectrometry.
Biochemistry (N.Y.). 40, 12983-12991
80. Wuttke, M., Müller, S., Nitsche, D.P., Paulsson, M., Hanisch, F., and Maurer, P.
(2001) Structural characterization of human recombinant and bone-derived bone
sialoprotein functional implications for cell attachment and hydroxyapatite binding. J.
Biol. Chem. 276, 36839-36848
81. Midura, R.J., McQuillan, D., Benham, K., Fisher, L.W., and Hascall, V.C. (1990) A
rat osteogenic cell line (UMR 106-01) synthesizes a highly sulfated form of bone
sialoprotein. J. Biol. Chem. 265, 5285-5291
82. Shapiro, H.S., Chen, J., Wrana, J.L., Zhang, Q., Blum, M., and Sodek, J. (1993)
Characterization of porcine bone sialoprotein: primary structure and cellular expression.
Matrix 13, 431-440
83. Fisher, L.W., McBride, O.W., Termine, J.D., and Young, M.F. (1990) Human bone
sialoprotein. Deduced protein sequence and chromosomal localization. J. Biol. Chem.
265, 2347-2351
84. Zaia, J., Boynton, R., Heinegård, D., and Barry, F. (2001) Posttranslational
modifications to human bone sialoprotein determined by mass spectrometry.
Biochemistry (N.Y.). 40, 12983-12991
85. Heinegård, D., Hultenby, K., Oldberg, Å., Reinholt, F., and Wendel, M. (1989)
Macromolecules in bone matrix. Connect. Tissue Res. 21, 3-14
86. Salih, E., Zhou, H.Y., and Glimcher, M.J. (1996) Phosphorylation of purified bovine
bone sialoprotein and osteopontin by protein kinases. J. Biol. Chem. 271, 16897-16905
87. Salih, E., and Flückiger, R. (2004) Complete topographical distribution of both the in
vivo and in vitro phosphorylation sites of bone sialoprotein and their biological
implications. J. Biol. Chem. 279, 19808-19815

35

88. Oldberg, A., Franzen, A., and Heinegaard, D. (1988) The primary structure of a cellbinding bone sialoprotein. J. Biol. Chem. 263, 19430-19432
89. Chen, J., McCulloch, C.A., and Sodek, J. (1993) Bone sialoprotein in developing
porcine dental tissues: cellular expression and comparison of tissue localization with
osteopontin and osteonectin. Arch. Oral Biol. 38, 241-249
90. Somerman, M., Sauk, J., Foster, R., Norris, K., Dickerson, K., and Argraves, W.
(1991) Cell attachment activity of cementum: bone sialoprotein identified in cementum.
J. Periodont. Res. 26, 10-16
91. Chen, J., Sasaguri, K., Sodek, J., Aufdemorte, T.B., Jiang, H., and Thomas, H.F.
(1998) Enamel epithelium expresses bone sialoprotein (BSP). Eur. J. Oral Sci. 106 Suppl
1, 331-336
92. Aplin, J.D. (1997) Adhesion molecules in implantation. Rev. Reprod. 2, 84-93
93. Ogbureke, K.U., and Fisher, L.W. (2004) Expression of SIBLINGs and their partner
MMPs in salivary glands. J. Dent. Res. 83, 664-670
94. Chenu, C., and Delmas, P.D. (1992) Platelets contribute to circulating levels of bone
sialoprotein in human. J. Bone Miner. Res. 7, 47-54
95. Chen, J., Shapiro, H.S., and Sodek, J. (1992) Development expression of bone
sialoprotein mRNA in rat mineralized connective tissues. J. Bone Miner. Res. 7, 987-997
96. Shen, Z., Heinegård, D., and Sommarin, Y. (1995) Distribution and expression of
cartilage oligomeric matrix protein and bone sialoprotein show marked changes during
rat femoral head development. Matrix Biol. 14, 773-781
97. Riminucci, M., Silvestrini, G., Bonucci, E., Fisher, L., Robey, P.G., and Bianco, P.
(1995) The anatomy of bone sialoprotein immunoreactive sites in bone as revealed by
combined ultrastructural histochemistry and immunohistochemistry. Calcif. Tissue Int.
57, 277-284

36

98. Fujisawa, R., Nodasaka, Y., and Kuboki, Y. (1995) Further characterization of
interaction between bone sialoprotein (BSP) and collagen. Calcif. Tissue Int. 56, 140-144
99. Bellahcène, A., Merville, M., and Castronovo, V. (1994) Expression of bone
sialoprotein, a bone matrix protein, in human breast cancer. Cancer Res. 54, 2823-2826
100. Bellahcene, A., Antoine, N., Clausse, N., Tagliabue, E., Fisher, L., Kerr, J., Jares, P.,
and Castronovo, V. (1996) Detection of bone sialoprotein in human breast cancer tissue
and cell lines at both protein and messenger ribonucleic acid levels. Lab. Invest. 75, 203210
101. Carlinfante, G., Vassiliou, D., Svensson, O., Wendel, M., Heinegård, D., and
Andersson, G. (2003) Differential expression of osteopontin and bone sialoprotein in
bone metastasis of breast and prostate carcinoma. Clin. Exp. Metastasis. 20, 437-444
102. Waltregny, D., Bellahcène, A., Castronovo, V., Dewé, W., de Leval, J., Van Riet, I.,
Fisher, L.W., Young, M., and Fernandez, P. (1998) Prognostic value of bone sialoprotein
expression in clinically localized human prostate cancer. J. Natl. Cancer Inst. 90, 10001008
103. Ryden, C., Yacoub, A., Hirsch, G., Wendel, M., Oldberg, A., and Ljungh, A. (1990)
Binding of bone sialoprotein to Staphylococcus epidermidis isolated from a patient with
chronic recurrent multifocal osteomyelitis. J. Infect. Dis. 161, 814-815
104. Helfrich, M.H., Nesbitt, S.A., Dorey, E.L., and Horton, M.A. (1992) Rat osteoclasts
adhere to a wide range of rgd (arg‐gly‐asp) peptide‐containing proteins, including the
bone sialoproteins and fibronectin, via a β3 integrin. J. Bone Miner. Res. 7, 335-343
105. Somerman, M.J., Fisher, L.W., Foster, R.A., and Sauk, J.J. (1988) Human bone
sialoprotein I and II enhance fibroblast attachment in vitro. Calcif. Tissue Int. 43, 50-53
106. Gordon, J.A., Tye, C.E., Sampaio, A.V., Underhill, T.M., Hunter, G.K., and
Goldberg, H.A. (2007) Bone sialoprotein expression enhances osteoblast differentiation
and matrix mineralization in vitro. Bone 41, 462-473

37

107. Gill, K.S., Beier, F., and Goldberg, H.A. (2008) Rho-ROCK signaling differentially
regulates chondrocyte spreading on fibronectin and bone sialoprotein. Am. J. Physiol.
295, C38-C49
108. Harris, N., Rattray, K., Tye, C., Underhill, T., Somerman, M., D’errico, J.,
Chambers, A., Hunter, G., and Goldberg, H. (2000) Functional analysis of bone
sialoprotein: identification of the hydroxyapatite-nucleating and cell-binding domains by
recombinant peptide expression and site-directed mutagenesis. Bone 27, 795-802
109. Zhou, H.Y., Takita, H., Fujisawa, R., Mizuno, M., and Kuboki, Y. (1995)
Stimulation by bone sialoprotein of calcification in osteoblast-like MC3T3-E1 cells.
Calcif. Tissue Int. 56, 403-407
110. Cooper, L., Yliheikkilä, P., Felton, D., and Whitson, S. (1998) Spatiotemporal
assessment of fetal bovine osteoblast culture differentiation indicates a role for BSP in
promoting differentiation. J. Bone Miner. Res. 13, 620-632
111. Ross, F., Chappel, J., Alvarez, J., Sander, D., Butler, W., Farach-Carson, M., Mintz,
K., Robey, P.G., Teitelbaum, S., and Cheresh, D. (1993) Interactions between the bone
matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta
3 potentiate bone resorption. J. Biol. Chem. 268, 9901-9907
112. Valverde, P., Zhang, J., Fix, A., Zhu, J., Ma, W., Tu, Q., and Chen, J. (2008)
Overexpression of bone sialoprotein leads to an uncoupling of bone formation and bone
resorption in mice. J. Bone Miner. Res. 23, 1775-1788
113. Boskey, A.L. (1995) Osteopontin and Related Phosphorylated Sialoproteins: Effects
on Mineralizationa. Ann. N.Y. Acad. Sci. 760, 249-256
114. Baht, G.S., Hunter, G.K., and Goldberg, H.A. (2008) Bone sialoprotein-collagen
interaction promotes hydroxyapatite nucleation. Matrix Biol. 27, 600-608
115. Goldberg, H.A., Warner, K.J., Li, M.C., and Hunter, G.K. (2001) Binding of bone
sialoprotein, osteopontin and synthetic polypeptides to hydroxyapatite. Connect. Tissue
Res. 42, 25-37

38

116. Harris, N., Rattray, K., Tye, C., Underhill, T., Somerman, M., D’errico, J.,
Chambers, A., Hunter, G., and Goldberg, H. (2000) Functional analysis of bone
sialoprotein: identification of the hydroxyapatite-nucleating and cell-binding domains by
recombinant peptide expression and site-directed mutagenesis. Bone 27, 795-802
117. Salih, E., Zhou, H., and Glimcher, M.J. (1996) Phosphorylation of purified bovine
bone sialoprotein and osteopontin by protein kinases. J. Biol. Chem. 271, 16897-16905
118. Lee, J.Y., Choo, J.E., Choi, Y.S., Park, J.B., Min, D.S., Lee, S.J., Rhyu, H.K., Jo,
I.H., Chung, C.P., and Park, Y.J. (2007) Assembly of collagen-binding peptide with
collagen as a bioactive scaffold for osteogenesis in vitro and in vivo. Biomaterials 28,
4257-4267
119. He, G., and George, A. (2004) Dentin matrix protein 1 immobilized on type I
collagen fibrils facilitates apatite deposition in vitro. J. Biol. Chem. 279, 11649-11656
120. Traub, W., Jodaikin, A., Arad, T., Veis, A., and Sabsay, B. (1992) Dentin
phosphophoryn binding to collagen fibrils. Matrix 12, 197-201
121. Dahl, T., Sabsay, B., and Veis, A. (1998) Type I collagen–phosphophoryn
interactions: specificity of the monomer–monomer binding. J. Struct. Biol. 123, 162-168

39

CHAPTER TWO

40

2.1

INTRODUCTION
A variety of approaches including electron microscopy, synthetic triple-helical

peptides, cyanogen bromide cleavage and chemical cross-linking have been utilized by
researchers in locating the binding site(s) of various proteins on type I collagen. Chemical
cross-linking appears to be a useful tool for mapping the BSP-binding site on collagen for
the reasons discussed below.
Chemical cross-linking is an important tool for studying protein-protein
interactions as it allows the formation of a covalent attachment between two interacting
proteins (1). The two chemical cross-linkers selected for studying the BSP-collagen
interaction in this study were ρ-azidophenacyl bromide (APB) and N-[4-(ρazidosalicylamido)butyl]-3’-(2’-pyridyldithio) propionamide (APDP). Both are
heterobifunctional cross-linkers possessing two different functional groups separated by a
spacer arm. APB has a bromoacetyl group, whereas APDP contains a pyridyl disulfide.
These functional groups are electrophilic, which makes them prone to react with the
cysteine residues (strong nucleophiles) found in the genetically modified single-cysteine
rBSP (1-100) peptides. The second functional group is a photoactivable group that nonspecifically inserts or adds to carbon-hydrogen or nitrogen-hydrogen bonds upon UV
exposure (1). It is advantageous for the cross-linkers to have this non-specific
photoactivable functional group because the type I collagen region that is in close
proximity in the BSP-cross-linker complex is unknown. The primary difference between
the chemical cross-linkers lies in the length of the spacer arm. The spacer arm of APDP is
approximately 2.1 nm (2) while APB has a spacer arm less than 1.2 nm in length (3). The
longer spacer arm of APDP may potentially interact with preferred amino acid residues
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on type I collagen that are further away from the BSP-collagen binding site and therefore
may increase the chances of forming BSP-type I collagen cross-linked products. In
addition, chemical cross-linking should not disrupt the triple-helical type I collagen
structure that is essential for binding to BSP (4). Furthermore, when chemical crosslinking is coupled with mass spectrometry (MS), the precise amino acid sequences
involved in the interactions can be determined.
The purpose of the present study is to use a chemical cross-linking method to map
the BSP-binding site on collagen. These experiments involve five single-cysteine rBSP
(1-100) mutants generated by site-directed mutagenesis, type I collagen and the chemical
cross-linkers: APB and APDP. Multiple approaches were taken to maximize the
efficiency of cross-linking and recovery of BSP-type I collagen cross-link products.

2.2

MATERIALS AND METHODS

2.2.1 MATERIALS
For protein expression and purification, E.coli (DE3) cells were purchased from
EMD Biosciences/Novagen (Gibbstown, NJ). Medical grade N2 was obtained from
Praxair Inc. (Mississauga, ON). Isopropyl β-D-thiogalactopyranoside (IPTG) was
purchased from Sigma-Aldrich (St. Louis, MO). Urea UltraPure grade was from BioShop
Canada (Burlington, ON).
For sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE):
ammonium persulfate (APS), N, N, N’, N’-tetramethylethane-1, 2-diamine (TEMED),
acrylamide/bis-acryalmide, SDS and pre-stained protein standards were all purchased
from Bio-Rad Laboratories (Hercules, CA). β-mercaptoethanol and glycine were
obtained from Thermo Fisher Scientific (Rockford, IL). Isopropanol was from VWR
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International (West Chester, PA). Imidazole, Stains-All and silver nitrate were all
purchased from Sigma-Aldrich.
For chemical cross-linking, the cross-linkers: APDP was purchased from Thermo
Fisher Scientific while APB was purchased from Sigma-Aldrich. The reducing agent,
Tris (2-carboxyethyl) phosphine hydrochloride (TCEP) was from Sigma-Aldrich. For
dissolving the chemical cross-linkers, dimethylformamide, (DMF) and methanol were
obtained from VWR International. Type I collagen was extracted from rat tail tendons in
our laboratory as previously described (5).

2.2.2 METHODS
2.2.2.1 Expression and purification of rBSP (1-100) mutants
A schematic diagram of BSP depicting the amino acids mutated to cysteine is
shown in Figure 2.1. The plasmids of the five single-cysteine mutants were generated by
site-directed mutagenesis by Aaron Langdon (past MSc student in Drs. Goldberg and
Hunter’s Laboratories). Three of the five single-cysteine rBSP (1-100) mutants (S16C,
Y31C and Y24C) were present in adequate amounts in the laboratory for the chemical
cross-linking experiments while the remaining two single-cysteine mutants (F36C and
S49C) were expressed and purified as described below.
The two single-cysteine rBSP (1-100) mutants (F36C and S49C) contain a pentaHis fusion tag at the C-terminus and were transformed into E.coli BL21 (DE3) cells and
grown in Luria broth (LB) containing 15 µg/ml kanamycin. When the optical density of
the cells reached 0.6 – 0.8, the cells were induced with 2 mM IPTG and grown for an
additional 4 hours. Sonication in His-column binding buffer (5 mM imidazole, 0.5 M
NaCl, 0.02 Tris-HCl, 6 M urea, pH 7.9) was used to lyse the bacterial cells.
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Subsequently, the cell lysate was fractionated by centrifugation and the supernatant
recovered.
The single-cysteine rBSP (1-100) mutants were purified extensively. The first
purification step was nickel affinity chromatography. The cell extract was loaded onto
Poly-prep chromatography columns (Bio-Rad) packed with 1.5 ml His-bind resin
(Novagen) that had been previously charged with 50 mM NiSO4. The columns were first
washed with 10 column volumes of binding buffer and the proteins eluted with 500 mM
imidazole-containing elution buffer (binding buffer containing 500 mM imidazole). The
eluted fractions were separated on 12.5% polyacrylamide gels using the Phastgel system
(Amersham Biosciences) and the gels stained with Stains-All (30 mM Tris-HCl pH 8.0,
7.5% formamide, 25% isopropanol, and 0.0025% Stains-All) and silver nitrate as
previously described (6).
The protein-enriched fractions from nickel affinity were pooled and diluted with
Mono A buffer (50 mM Tris-HCl, 7M urea, pH 7.4) and purified further by ion-exchange
chromatography. The fractions were loaded onto a Q Sepharose Fast Flow 1 x 10 cm
column (Fast Q) connected to the Fast Protein Liquid Chromatography (FPLC) system
(AKTA-purifier Amersham Pharmacia Biotech). Proteins were eluted with a linear
gradient of sodium chloride (0 – 500 mM) at a flow rate of 2.0 ml/min. Fractions of 1 ml
were collected and selected fractions stained with Stains-All and silver. Fractions
containing the peptide of interest were pooled and concentrated to a volume of
approximately 2.5 ml using a pressurized Amicon ultrafiltration apparatus with an YM-3
(3-kDa cutoff) membrane (Millipore).
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The concentrated protein-enriched fractions were purified further by gel filtration
using a Superdex 200PG column (1.6 cm x 60 cm) (Amersham Biosciences) in 50 mM
Tris, 4 M urea, 200 mM NaCl, pH 7.4. The fractions containing the protein of interest
(determined by SDS-PAGE) were dialyzed using 10 mM ammonium bicarbonate for 72
hours at 4° C using a 3-kDa cutoff Spectra/Por dialysis membrane (Spectrum
Laboratories). After dialysis, the fractions were aliquoted and lyophilized. Finally, the
purity and quantity of the protein samples were determined by Bicinchoninic acid (BCA)
assays, amino acid analysis (Advance Protein Technology Centre, The Hospital for Sick
Children, Toronto) and MALDI mass spectrometry (Bruker® Reflex IV MALDI TOF
MS, Department of Biochemistry, UWO, London).
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Figure 2.1 Schematic diagram of BSP depicting the amino acids mutated to cysteine.
BSP contains approximately 300 amino acid residues (as indicated by the numbers). The
amino acids mutated to cysteine for chemical cross-linking are highlighted in orange. The
selected amino acids are within and surrounding the collagen-binding region.
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2.2.2.2 Chemical Cross-Linking with APB and APDP and Purified using
TALON® His6-Tag Cobalt Resin
A general overview of the chemical cross-linking protocol is shown in Figure 2.2.
Chemical cross-linking reactions between single-cysteine rBSP mutants (S16C,
Y24C, Y31C, F36C and S49C) and type I collagen were carried out using
heterobifunctional cross-linkers APB and APDP. Additionally, control cross-linking
reactions between wild-type (WT) rBSP (1-100) and type I collagen using APB and
APDP were performed. These reactions served as the control as WT rBSP (1-100) does
not contain a cysteine residue that is required for cross-linking to occur.
First, bond-breaker solution (9 mM TCEP in 2x PBS) was added to singlecysteine BSP (1-100) mutants (1 mg/mL dissolved in 2x PBS, 3 mM EDTA pH 7.5) and
incubated for 30 min. Subsequently, the bond-breaker solution was removed by buffer
exchange using Amicon® Ultra-0.5 centrifugal filter units. The single-cysteine BSP
mutants were incubated with one of the chemical cross-linkers: 50 mM APDP in DMF or
50 mM APB in methanol for 30 min in the dark. Excess cross-linkers were then removed
by buffer exchange using Amicon® Ultra-0.5 centrifugal filter units. Type I collagen (1
mg/mL) in 5 mM acetic acid was then added to the reaction mixture and incubated in the
dark for 1 hour. To induce chemical cross-link formation, the reaction mixture was
irradiated with a UV ultraviolent lamp (Thermo Scientific Pierce) at a wavelength of 365
nm for APDP and at 254 nm for APB for 5 min.
In order to maximize the recovery of successful BSP-type I collagen cross-link
products, reactions were purified using TALON® His6-Tag cobalt resin (Clontech
Laboratories) and concentrated using Amicon® Ultra-4 centrifugal filter units and
Amicon® Ultra-0.5 centrifugal filter units. The reactions were loaded onto a 6% SDS-
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PAGE gel in the absence of a reducing agent and run at 80 V until the separating gel was
reached where the voltage was increased to 120 V. The gels were then stained with
Stains-All and silver (6) for analysis.
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Figure 2.2 An overview of the chemical cross-linking protocol. Chemical cross-linking
reactions between single-cysteine rBSP (1-100) mutants and type I collagen were carried
out using the cross-linkers APB or APDP. The chemical cross-linking reactions were
purified using a His6 –Tag cobalt resin or nickel magnetic beads and then concentrated
using centrifugal filter devices. The products of the cross-linking reactions were then
analyzed using Stains-All and silver.
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2.2.2.3 Chemical Cross-Linking using APDP and Purification using Millipore
PureProteomeTMNickel Magnetic Beads
In hopes to increase the recovery of successfully cross-linked BSP-type I collagen
complexes, the purification resin was changed from the TALON® His6-Tag cobalt resin
(Clontech Laboratories) to nickel magnetic beads (Millipore PureProteomeTM).
Chemical cross-linking reactions between single-cysteine BSP mutants (S49C and
F36C) and type I collagen were carried out using APDP as previously described. The
single-cysteine mutants, S49C and F36C, were used for this experiment as these two
mutants showed higher levels of potential cross-links over the other single-cysteine
mutants. Additionally, the cross-linker APDP was used rather than APB for the same
reasons.
After chemical cross-linking, the reactions were purified using an aliquot of 200
µL of nickel magnetic beads present in a 1.5 mL microcentrifuge tube. The magnetic
beads were first equilibrated with 500 µL of equilibration buffer (50 mM sodium
phosphate, 300 mM NaCl, pH 8) for 1 min at 22°C. The equilibration buffer was
removed by placing a small circular magnet (Staples®, Canada) at the side of the
microcentrifuge tube, resulting in the magnetic beads adhering to the side of the tubes
allowing for the buffer to be easily removed by a pipette. The protein sample was then
added to the magnetic beads and incubated for 1 hour at 22°C. Subsequently, five
consecutive washes using the wash buffer (50 mM sodium phosphate, 300 mM NaCl, pH
8) were performed to remove any unbound proteins. Elution of the protein was done by
adding an aliquot of 100 µL of elution buffer (50 mM sodium phosphate, 300 mM
sodium chloride, 300 mM imidazole, pH 8) and incubation for 2 min at 22°C. The eluted
fraction was collected with use of the magnet and the recovered solutions concentrated
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and analyzed by SDS-PAGE and staining with Stains-All and silver (as previously
described) for analysis of potential BSP-type I collagen cross-links.
2.2.2.4 Characterization of the Additional Bands after Chemical Cross-Linking
To determine whether the high-molecular-weight bands present after chemical
cross-linking are rBSP (1-100) cross-linked to itself, cross-linking reactions were carried
out with the single-cysteine rBSP (1-100) F36C mutant and type I collagen using APDP
as previously described. The single-cysteine rBSP (1-100) F36C mutant was chosen for
this experiment as this mutant showed high levels of the high-molecular-weight bands
after cross-linking. Prior to loading the samples onto a 6% SDS-PAGE gel, the samples
were heated to 95°C in the presence or absence of a reducing agent (β-mercaptoethanol)
for 10 min. In the case where the bands are a result of the single-cysteine rBSP (1-100)
mutants self-cross-linking, the disulfide bonds will break in the presence of βmercaptoethanol and the polymeric BSP will be reduced to monomeric rBSP (1-100)
peptides. The gel was then stained with Stains-All and silver for analysis. Additionally,
to ensure that the sensitivity and detection of type I collagen is not decreased with Stainsall and silver, a second 6% SDS-PAGE gel was stained with only silver nitrate (6).
2.2.2.5 Chemical Cross-Linking using APDP and Purification using Gel
Filtration and Millipore PureProteomeTM Nickel Magnetic Beads
Another attempt to increase the recovery of successful BSP-type I collagen crosslinked polymers was to use two purification approaches: gel filtration and nickel
magnetic beads. Chemical cross-linking reactions between the single-cysteine BSP
mutant (S49C) and type I collagen were carried out using APDP as previously described.
Prior to purification of the cross-linking reactions using nickel magnetic beads, the
reaction mixture was purified by gel filtration on a Superdex 200PG column. This step
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should separate the lower-molecular-weight single-cysteine rBSP (1-100) mutants that
are not cross-linked to collagen from larger-molecular-weight cross-linked polymers. The
removal of the potentially competing binding ligand for the nickel resin should enhance
binding and recovery of rBSP-type I collagen cross-linked products. Furthermore, the
higher-molecular-weight fractions containing the co-eluting unbound type I collagen
should not bind to the nickel resin since it does not contain the His6).

2.3

RESULTS

2.3.1 Expression and purification of rBSP (1-100) mutants
Two single-cysteine rBSP (1-100) mutants (F36C and S49C) were overexpressed
in E.coli BL21 (DE3) cells and purified extensively using three purification columns. The
first purification step was nickel affinity chromatography. The eluted fractions were
separated on 12.5% polyacrylamide gels and stained with Stains-All and silver to
determine the purity of the fractions (results not shown).
The protein-enriched fractions from nickel affinity were pooled and further
purified by ion exchange using a Fast Q column connected to the FPLC system. The
presence of proteins was monitored spectrophotometrically at 230 and 280 nm (Figure
2.3A). Selected fractions were separated on 12.5% polyacrylamide gels and stained with
Stains-All and silver for analysis (Figure 2.3A, insert).
The protein-enriched fractions from ion exchange were pooled and loaded onto a
Superdex 200PG column and monitored spectrophotometrically at 230 and 280 nm for
the presence of protein (Figure 2.3B). The fractions containing the protein of interest
(Figure 2.3B, insert) were dialyzed against 10 mM ammonium bicarbonate and then
aliquoted and lyophilized.
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The purity of the protein samples were further verified by MALDI mass
spectrometry. The single-cysteine rBSP (1-100) F36C mutant with a 5xHis tag was
detected by MALDI mass spectrometry as a single peak at 12,029 Da. The theoretical
mass based on the known amino acid sequence is 12,036 Da. Additionally, the quantity
of the protein samples were determined by BCA assays (data not shown).
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B

Figure 2.3 Chromatograms of the single-cysteine rBSP (1-100) F36C mutant
separated by ion exchange and gel filtration chromatography.
The protein-enriched fractions from nickel affinity were pooled and diluted with Mono A
buffer (50 mM Tris-HCl, 7 M urea, pH 7.4) and loaded onto a (A) Fast Q packed column
connected to the FPLC system. Proteins were eluted with a linear gradient of 0-0.5 M
NaCl. Fractions of 1 mL were collected and selected fractions (green box) were purified
further with a (B) Superdex 200PG gel filtration column. The fractions containing the
protein of interest were pooled and lyophilized (green box). The absorbance at 280 nm is
in blue and the absorbance at 230 nm is in red.
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2.3.2 BSP-type I collagen cross-linking reactions using APB
Chemical cross-linking between the five single-cysteine rBSP (1-100) mutants
was carried out using APB. Subsequently, type I collagen (1 mg/ml) in 5 mM acetic acid
was then added to the reaction mixture. The products of the cross-linking reactions were
loaded onto a 6% SDS-PAGE and analyzed by Stains-All and silver (Figure 2.4).
The band corresponding to the single-cysteine rBSP (1-100) mutants appears near
18 kDa on SDS-PAGE, even though the actual molecular weight (based on the known
amino acid sequence) is approximately 12.2 kDa. With regards to type I collagen, the
molecular weight of each collagen α-chain is approximately 97 kDa (based on the known
amino acid sequence), however; based on SDS-PAGE, the α1 and α2 chains migrate much
slower than expected: at approximately 120 kDa and 110 kDa, respectively. From the
known molecular weights of the rBSP (1-100) mutants and the collagen α-chains, a
successful cross-link would be approximately 110 kDa.
However, due to the slow migration of rBSP (1-100) mutants and collagen α
chains, the successful BSP-type I collagen cross-link would be in the range of 128 kDa to
138 kDa. Therefore, a band corresponding to a successful cross-link BSP-collagen
product would be immediately above the α1 and α2 chains of type I collagen (Figure 2.4;
the lanes labeled “coll” indicate the position of the α1 and α2 chains). There appears to be
a band present, albeit weakly-stained, at approximately 130 kDa that may correspond to a
BSP-collagen cross-link (Figure 2.4; as indicated by the purple arrow). Furthermore, this
possible cross-link at 130 kDa was not observed in the control cross-linking reactions
using rBSP (1-100). However, there are numerous additional bands above and below 130
kDa. As well, the generally weakly stained band suggests recovery of the cross-linked
protein is low and/or the cross-linking efficiency is low.
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Figure 2.4 Analysis of BSP-type I collagen cross-linking reactions using APB.
Chemical cross-linking reactions between single-cysteine BSP mutants (S16C, Y24C,
Y31C, F36C and S49C) and type I collagen were carried out using APB. Reactions were
purified using TALON® His6-Tag cobalt resin and concentrated using Amicon® Ultra-4
centrifugal filter units and Amicon® Ultra-0.5 centrifugal filter units prior to loading
onto a 6% SDS-PAGE gel and stained with Stains-All and silver for analysis. Potential
cross-links between BSP and collagen are present at approximately 130 kDa (purple
arrow). “M” indicates the molecular marker; rBSP refers to the wild type peptide.
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2.3.3 BSP-Type I Collagen Cross-Linking Reactions using APDP
An attempt was made to increase the cross-linking efficiency between BSP and
type I collagen by using APDP (2.1 nm), which contains a longer spacer arm than APB
(1.2 nm).
Once again, there appears to be a band, albeit weakly stained, at approximately
130 kDa corresponding to a potential BSP-collagen cross-link (Figure 2.5; as indicated
by the purple arrow). Furthermore, this possible cross-link at 130 kDa was not observed
in the control cross-linking reactions using rBSP (1-100). However, the same issues are
evident: there are additional bands above and below the potential cross-linked product.
Additionally, the weakly stained band suggests recovery of the cross-linked protein is
low and/or the cross-linking efficiency is low.
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Figure 2.5 Analysis of BSP-type I collagen cross-linking reactions using APDP.
Chemical cross-linking reactions between single-cysteine rBSP mutants (S16C, Y24C,
Y31C, F36C and S49C) and type I collagen were carried out using APDP. Reactions
were purified using TALON® His6-Tag cobalt resin, concentrated by centrifugal
ultrafiltration, and analyzed by 6% SDS-PAGE and staining with Stains-All and silver.
Potential cross-links between BSP and collagen are present at approximately 130 kDa
(purple arrow). “M” indicates the molecular-weight marker.
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2.3.4 BSP-Type I collagen Cross-Linking Reactions using APDP and
Purified using Millipore PureProteomeTM Nickel Magnetic Bead
In hopes to enhance the cross-linking efficiency, the purification resin was
changed from the TALON® His6-tag cobalt resin to Millipore PureProteomeTM nickel
magnetic beads. Chemical cross-linking reactions between single-cysteine rBSP mutants
(S49C and F36C) and type I collagen were carried out using APDP as previously
described.
Unfortunately, no increase in the recovery of the cross-linked products was
observed (as indicated by the weakly stained band at approximately 130 kDa; Figure 2.6).
As well, there are additional bands above and below the potential BSP-type I collagen
cross-link present, suggesting this purification resin did not increase the recovery of the
cross-linked products in the expected manner.

2.3.5 Characterization of the Additional Bands Present after CrossLinking
To determine whether the additional bands above and below the potential BSPcollagen cross-link in Figures 2.4 and 2.5 are the result of the single-cysteine rBSP (1100) mutants cross-linking to itself, chemical cross-linking reactions with F36C, WT
rBSP (1-100) and type I collagen were performed using APDP. Prior to loading the
samples onto a 6% SDS-PAGE gel, the samples were heated to 95°C in the presence or
absence of a reducing agent (β-mercaptoethanol) for 10 min. The gels were stained with
Stains-All (Figure 2.7A), the combined Stains-All silver protocol (Figure 2.7B) or only
silver (Figure 2.7C).
The additional bands, above and below the potential cross-linked product (Figure
2.7A and 2.7B yellow box) from samples not treated with β-mercaptoethanol, were not
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observed when β-mercaptoethanol was added (Figure 2.7A and 2.7B; green box). As
well, the blue smear present with Stains-All in the absence of β-mercaptoethanol is
indicative of an acidic protein (Figure 2.7A). These findings suggest the bands are a
result of the single-cysteine rBSP (1-100) mutants cross-linking to itself.
The 6% SDS-PAGE stained with silver nitrate alone (Figure 2.7C), ensured that
sensitivity and detection of type I collagen is not decreased with Stains-All and silver. No
apparent differences are observed between the two staining protocols.
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Figure 2.6 Analysis of BSP-type I collagen cross-linking reactions using APDP and
purified using nickel magnetic beads.
Chemical cross-linking reactions between single-cysteine BSP mutants (S49C and F36C)
and type I collagen were carried out using APDP. Reactions were purified using the
nickel magnetic beads (Millipore PureProteomeTM) and concentrated by centrifugal
ultrafiltration prior to loading onto a 6% SDS-PAGE gel and staining with Stains-All and
silver for analysis. “M” indicates the molecular marker.
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B

A
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Figure 2.7 Characterization of the additional bands present after cross-linking.
Chemical cross-linking was carried out using F36C, WT rBSP (1-100) and type I
collagen using APDP to determine whether the bands observed in (Figures 2.4 and 2.5)
are the result of single-cysteine rBSP mutants self-cross-linking. Prior to loading the
samples onto a 6% SDS-PAGE gel, the samples were heated to 95°C in the presence or
absence of β-mercaptoethanol. The gels were then stained first with (A) Stains-All and
followed by (B) silver for analysis. The bands that appear as a blue smear (yellow box)
are the result of single cysteine rBSP (1-100) F36C mutant cross-linking to itself and are
reduced to monomeric rBSP (1-100) F36C in the presence of β-mercaptoethanol (green
box). Identical samples were electrophoresed on a second 6% SDS-PAGE gel and stained
with silver only (C). “M” indicates the molecular marker.
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2.3.6 BSP-type I collagen cross-linking reactions using APDP and
purified using gel filtration and nickel magnetic beads
In order to increase the recovery of successful BSP-type I collagen cross-linked
polymers, two purification approaches were used: gel filtration and nickel magnetic
beads. Chemical cross-linking reactions between the single-cysteine BSP mutant (S49C)
and type I collagen were carried out using APDP as previously described. Prior to
purification of the cross-linking reactions using nickel magnetic beads, the reaction
mixture was separated by gel filtration on a Superdex 200PG column. This step separated
the single-cysteine rBSP (1-100), and the smaller rBSP (1-100) polymers that were not
cross-linked to collagen from larger molecular weight cross-linked polymers. The
fractions consistent with containing BSP-type I collagen cross-links were collected
(Figure 2.8A, orange box), and purified further using the nickel magnetic beads.
Unfortunately, from the gel electrophoresis analysis, no increase in the efficiency of the
cross-linked products was observed using this approach (Figure 2.8B).
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Figure 2.8 BSP-type I collagen cross-linking reactions using APDP and purification
by gel filtration and nickel magnetic beads.
Chemical cross-linking reactions between the single-cysteine BSP mutant (S49C) and
type I collagen were carried out using APDP. The cross-linking reactions were purified
by gel filtration and nickel magnetic beads. (A) Gel filtration on a Superdex 200PG
column. The fractions potentially containing BSP-type I collagen cross-links were
collected (A; orange box) and purified further using nickel magnetic beads. The purified
samples were then loaded onto a 6% SDS-PAGE gel and stained with (B) Stains-All and
silver for analysis. “M” indicates the molecular-weight marker.
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2.4

DISCUSSION
Chemical cross-linking is a good protocol for mapping the BSP-binding region on

type I collagen as it allows the formation of a covalent attachment between two
interacting proteins. A major advantage is that when coupled with MS it facilitates the
determination of the BSP-binding site on collagen to the amino-acid level. Once the
covalent cross-linked product is characterized by MS, our goal would have been to use
molecular modeling (MM) to simulate the BSP-type I collagen interaction and to pinpoint
the interacting amino acids (7).
Multiple approaches were taken to maximize the efficiency and/or recovery of
successful BSP-type I collagen cross-linked products. However, the efficiency and/or
recovery of the cross-linked products observed from the gels stained with Stains-All and
silver were unexpectedly low in all instances and therefore the complexes were not
further characterized.

2.4.1 Single-cysteine rBSP (1-100) mutants
To maximize the chances of a successful BSP-type I collagen cross-link, five
single-cysteine mutants were generated. The residues selected for cysteine substitutions
are within and surrounding the type I collagen-binding domain in BSP. Within the
collagen-binding region, the residues selected for cysteine substitution (Y24, Y31 and
F36) are bulky, aromatic residues and were chosen in order to minimize steric hindrance
between rBSP (1-100) peptides and collagen in the presence of cross-linker agents.
Residues surrounding the collagen-binding domain were selected in case the mutations
within the collagen-binding region interfered with the BSP-collagen interaction. The
residues selected for cysteine substitution (S16 and S49) had chemically similar side-

65

chains as steric hindrance was less of a consideration. Additionally, the selected residues
on BSP were mutated to cysteine as BSP does not contain any cysteine residues and
therefore it is known where on the protein the cross-linker would be bound.

2.4.2 BSP-type I collagen cross-linking reactions using APB and APDP
There was a possible BSP-collagen cross-link at approximately 130 kDa when the
cross-linkers APB and APDP were used. The presence of weakly stained bands suggests
the cross-linking efficiency and/or recovery of the cross-linked products is low. This was
unexpected as the chemical cross-linkers APB and APDP have been used in many crosslinking experiments studying protein-protein interactions. APB has been utilized to
identify the binding sites within the b subunit of E.coli ATP synthase that are responsible
for interacting with α, β, and a subunits (8). APB was also used to study the interaction
between yeast cytochrome c and cytochrome c peroxidase (9). With regards to APDP,
this cross-linker has been utilized by Yasui et al. to study the interaction between a
pigment epithelium-derived factor (PEDF) and type I collagen (10).
In addition, multiple steps were taken to maximize the cross-linking efficiency
and recovery of the successful BSP-collagen cross-linked complex. Following the
reaction of APB or APDP with single-cysteine rBSP (1-100) mutants, excess crosslinkers were removed by buffer exchange. This step was carried out to reduce nonspecific cross-link formation. Additionally, following UV exposure to induce cross-link
formation, the reactions were affinity purified and concentrated. These two steps were
carried out to maximize the recovery of successful BSP-type I collagen cross-link
products.
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It is also puzzling that there are unbound α1 and α2 collagen chains present since
the cross-linking reaction products were affinity purified to recover the poly-Hiscontaining proteins. A potential explanation for this is that collagen bound nonspecifically to the purification resin. Therefore a different purification protocol was used,
as discussed below.

2.4.3 Chemical cross-linking using APDP and purification using nickel
magnetic beads
Using nickel magnetic beads we observed no increase in the amount of the BSPcollagen cross-linked products (Figure 2.6). This was unexpected since the nickel
magnetic beads have been shown to achieve high purity and yield of His6-tag proteins
(11, 12). The single-cysteine mutants, S49C and F36C were used for this experiment
because they showed higher levels of potential cross-links over the other single-cysteine
mutants. Additionally, the cross-linker APDP was used rather than APB for the same
reasons. However in spite of all the modifications, cross-linked product was not evident
in high yield. A potential explanation of why this purification resin did not enhance the
recovery lies in the additional bands present after chemical cross-linking.

2.4.4 Characterization of the additional bands present after crosslinking
Since the additional bands (in the absence of β-mercaptoethanol) were not
observed when β-mercaptoethanol (disulfide bond ‘breaker’) was added (Figure 2.7A and
2.7B; green box), these bands are likely a result of the single-cysteine rBSP (1-100)
mutants cross-linking to itself. Additional evidence that the bands are a result of the
single-cysteine rBSP (1-100) mutants cross-linking to itself is the blue staining of these
higher molecular weight bands with Stains-All, which is indicative of an acidic protein.
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Since there was a concern that excess rBSP peptide, both unreacted and cross-linked to
itself, would interfere with the rBSP-collagen product binding to the nickel affinity
column, a strategy to remove the majority of the unwanted peptide was developed.

2.4.5 BSP-type I collagen cross-linking reactions using APDP and
purified using gel filtration and nickel magnetic beads
No increase in the amount of the higher molecular weight recovered cross-linked
products was observed when the single-cysteine rBSP (1-100) mutants and smaller
polymeric BSP that are not cross-linked to collagen were first removed by gel filtration
(Figure 2.8B). However, the low level of BSP-collagen cross-linked products observed is
not likely due to the cysteine residues being unreactive. Previous work with fluorescein5-maleimide demonstrated that the cysteine residues found in the single-cysteine (1-100)
rBSP peptides are available and able to react with the chemical cross-linkers
(unpublished data). A potential explanation for the low BSP-collagen cross-linked
products lie in the spacer arm, perhaps it was not long enough to reach a collagen amino
acid from the cysteine residue of the single-cysteine rBSP (1-100) peptide. However,
these two cross-linkers possess the longest spacer arms among commercially available
heterobifunctional cysteine-reactive cross-linkers with a photoactivable group. For
example, benzophenone-4-maleimide (BPM) has a spacer arm that is less than 0.9 nm. In
addition, BPM has a photoactivable group that has been shown to have a preference for
methionine residues. This may potentially decrease the BSP-collagen cross-linked
products formed as methionine residues are fairly spread out within collagen molecules
(13). In order to increase the sensitivity of detection, some researchers have utilized
trifunctional cross-linkers possessing a biotin group such as sulfosuccinimidyl-2-[6(biotinamido)-2-(p-azidobenzamido)-hexanoamido] ethyl-1,3=-dithiopropionate (sulfo-
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SBED) (14, 15). Subsequently, the cross-linked products would be enriched through
affinity chromatography. However, since the cross-linking efficiency is low; this
approach would require a sufficiently large amount of protein in order to obtain the
desired amount BSP-collagen cross-linked product. Therefore, due to these difficulties in
obtaining sufficient BSP-collagen cross-linked product, an alternative protocol using
rotary-shadowing transmission electron microscopy (rotary-shadowing TEM) was used to
map the BSP-binding site on type I collagen (discussed in the next chapter).

69

2.6

REFERENCES

1. Sinz, A. (2003) Chemical cross‐linking and mass spectrometry for mapping
three‐dimensional structures of proteins and protein complexes. J. Mass. Spectrom. 38,
1225-1237
2. Hermanson, G.T. (2008) Bioconjugate Techniques, Second Edition, Academic Press
Elsevier, London, UK
3. Soubannier, V., Rusconi, F., Vaillier, J., Arselin, G., Chaignepain, S., Graves, P.,
Schmitter, J., Zhang, J.L., Mueller, D., and Velours, J. (1999) The second stalk of the
yeast ATP synthase complex: identification of subunits showing cross-links with known
positions of subunit 4 (subunit b). Biochemistry (N.Y.). 38, 15017-15024
4. Baht, G.S., Hunter, G.K., and Goldberg, H.A. (2008) Bone sialoprotein-collagen
interaction promotes hydroxyapatite nucleation. Matrix Biol. 27, 600-608
5. Hunter, G.K., Poitras, M.S., Underhill, T.M., Grynpas, M.D., and Goldberg, H.A.
(2001) Induction of collagen mineralization by a bone sialoprotein–decorin chimeric
protein. J. Biomed. Mater. Res. 55, 496-502
6. Goldberg, H.A., and Warner, K.J. (1997) The staining of acidic proteins on
polyacrylamide gels: enhanced sensitivity and stability of "Stains-all" staining in
combination with silver nitrate. Anal. Biochem. 251, 227-233
7. . Mouradov, D., King, G., Ross, I.L., Forwood, J.K., Hume, D.A., Sinz, A., Martin,
J.L., Kobe, B., and Huber, T. (2008) Protein structure determination using a combination
of cross-linking, mass spectrometry, and molecular modeling. Methods Mol. Biol. 426,
459-474
8. McLachlin, D.T., Coveny, A.M., Clark, S.M., and Dunn, S.D. (2000) Site-directed
cross-linking of b to the alpha, beta, and a subunits of the Escherichia coli ATP synthase.
J. Biol. Chem. 275, 17571-17577

70

9. Wang, Y., and Margoliash, E. (1995) Enzymic activities of covalent 1: 1 complexes of
cytochrome c and cytochrome c peroxidase. Biochemistry (N.Y.). 34, 1948-1958
10. Yasui, N., and Koide, T. (2003) Collagen-protein interactions mapped by
phototriggered thiol introduction. J. Am. Chem. Soc. 125, 15728-15729
11. Smith, C. (2005) Striving for purity: advances in protein purification. Nat. Methods.
2, 71-77
12. Waseh, S., Hanifi-Moghaddam, P., Coleman, R., Masotti, M., Ryan, S., Foss, M.,
MacKenzie, R., Henry, M., Szymanski, C.M., and Tanha, J. (2010) Orally administered
P22 phage tailspike protein reduces Salmonella colonization in chickens: Prospects of a
novel therapy against bacterial infections. PLoS One. 5, e13904
13. Wittelsberger, A., Thomas, B.E., Mierke, D.F., and Rosenblatt, M. (2006) Methionine
acts as a “magnet” in photoaffinity crosslinking experiments. FEBS Lett. 580, 1872-1876
14. Sinz, A., Kalkhof, S., and Ihling, C. (2005) Mapping protein interfaces by a
trifunctional cross-linker combined with MALDI-TOF and ESI-FTICR mass
spectrometry. J. Am. Soc. Mass. Spectrom. 16, 1921-1931
15. Rao, G., Santhoshkumar, P., and Sharma, K.K. (2008) Anti-chaperone βA3/A1102117 peptide interacting sites in human αB-crystallin. Mol. Vis. 14, 666-674

71

CHAPTER THREE

72

3.1

INTRODUCTION
Rotary-shadowing transmission electron microscopy (rotary-shadowing TEM) is

an excellent tool for identifying protein binding sites on other proteins because it offers
high-contrast visualization of individual macromolecules. This is made possible by
evaporation of a contrast-enhancing metal (e.g. platinum) that produces a fine grain onto
the specimens at a low angle (i.e. 5-15°) (1-3). Researchers have utilized rotaryshadowing TEM extensively for locating the type I collagen-binding site(s) of various
proteins such as proteoglycans, dentin phosphophoryn (DPP) and integrins (4-7). For
instance, rotary-shadowing TEM shows DPP, a proposed mediator of mineralization in
dentin, binding to type I collagen at a distance that is approximately 210 nm from the Nterminal end of the collagen molecule. This corresponds to DPP covering residues 698 to
750 on collagen upon binding (an overlap region of the collagen fibril) (4). Using goldlabeling EM, San Antonio et al., mapped the heparin-binding location to the N-terminal
region of collagen (5). This method has also been used to map the collagen-binding sites
for integrins α1β1 and α2β1 (6). Similarly, decorin has been mapped to a region near the Cterminus, which corresponds to the c1 band in the overlap region of the collagen fibril Dperiod (7). Collectively, these studies demonstrate rotary-shadowing TEM to be a
promising tool for studies of protein interactions with collagen.
Since studies on chemical cross-linking of BSP to type I collagen were hampered
because of low yield, rotary-shadowing TEM was used to visualize the BSP-binding site
on type I collagen. Using this method, the structures of type I collagen (8) and BSP (9)
have been successfully elucidated by others. Type I collagen appears semi-flexible and
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rod-like, while BSP appears as a monomer with a 10-nm globular structure that is linked
to an elongated thread-like structure of ~25 nm.

3.2

MATERIALS AND METHODS

3.2.1 MATERIALS
Type I collagen was either extracted from rat tail tendons [as previously described
(10)], or obtained commercially from Sigma-Aldrich (St. Louis, MO). TEM copper
grids, 400 mesh, and mica were from Electron Microscopy Sciences (Hatfield, PA).
Ammonium formate and acetic acid were purchased from Sigma-Aldrich. Glycerol was
from EMD Biosciences/Novagen (Gibbstown, NJ). Carbon rods and platinum were
purchased from SPI Supplies (West Chester, PA).

3.2.2 METHODS
3.2.2.1 Rotary-shadowing TEM
A general overview of the protocol is illustrated in Figure 3.1.
The interaction of BSP and type I collagen was examined using glycerolspraying/low-angle rotary-shadowing TEM (2, 3) at The Microscopy Imaging Laboratory
(University of Toronto). Full-length rBSP was dissolved in 70% glycerol/30% 0.01 M
ammonium formate to a final concentration of 50 µg/ml. Type I collagen (1 mg/ml
prepared in-house or 1 mg/ml obtained from Sigma) was stored in acetic acid, and
dialyzed with 0.01 M ammonium formate, pH 7.2, prior to use. An anti-collagen I
antibody (Sigma) used to identify the N-terminal end of the collagen molecules was
diluted to 5 µg/ml in 70% glycerol/30% 0.01 M ammonium formate (v/v).
The samples prepared for rotary-shadowing TEM are outlined in Figure 3.2. An
aliquot of 10 µl of each sample was mixed together in a microcentrifuge tube, vortexed
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and incubated overnight at 4°C. A 20 µl aliquot of the sample mixture was then sprayed
onto freshly cleaved mica sheets (Electron Microscopy Sciences) with a pressurized
duster (Lyreco, Markham ON) at a distance of approximately 30 cm. In addition, the
sample buffer (70% glycerol/30% 0.01 M ammonium formate) was rotary-shadowed and
served as a control. Micas with the samples were then dried in vacuum and rotaryshadowed with platinum with an electron-bombarded source at an angle of 5°.
Subsequently, the samples were backcoated at 90° with a carbon film. The films were
then floated off the mica and transferred onto three 400-mesh TEM copper grids for
analysis in a Philips CM-10 TEM at the UWO Biotron operating at 80 kV. The images
were taken using the AMT Image software and measurements were made with the
ImageJ software (NIH).
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Figure 3.1 An overview of the rotary-shadowing TEM protocol.
Full-length rBSP (50 µg/ml) and type I collagen (1mg/ml) were incubated overnight at 4
°C and then sprayed onto freshly cleaved mica sheets. Mica containing the samples were
then rotary-shadowed with platinum and backcoated with a carbon film. The films were
then floated off the mica and transferred onto 400-mesh copper grids for TEM analysis.
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Figure 3.2 Sample preparations for rotary-shadowing TEM.
The different sample preparations for rotary-shadowing TEM using rBSP (50 µl/ml), two
sources of type I collagen (prepared in-house and purchased from Sigma), and a Nterminal type I collagen antibody (5 µg/ml) are shown.
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3.3

RESULTS

3.3.1 Rotary-shadowing TEM of recombinant BSP
Rotary-shadowing TEM shows rBSP as a monomer possessing a 10-nm globular
structure linked to an elongated thread-like structure of ~25 nm (Figure 3.3B). The
schematic diagram in (Figure 3.3C) illustrates the shape of rBSP particles found in
(Figure 3.3B), which is consistent with the literature (9).

3.3.2 Type I collagen rotary-shadowed with platinum
Two sources of type I collagen (prepared in-house and purchased from Sigma)
were rotary-shadowed with platinum. The TEM images in (Figure 3.4) show
representative type I collagen molecules observed upon examination of more than 50
collagen molecules (from multiple TEM copper grids) for each collagen source. The
majority of the collagen molecules from Sigma (greater than 90%) appear semi-flexible
and rod-like. Measurements of the collagen lengths with the ImageJ software reveal a
mean of 270 nm and a standard deviation of 32 (at the 95% confidence level). In contrast,
the lengths of the collagen molecules prepared in-house are quite varied. In addition to
semi-flexible and rod-like collagen molecules, collagen molecules with lengths of 700
nm or greater are present, possibly indicative of aggregation.

3.3.3 N-terminal type I collagen antibodies rotary-shadowed with
platinum
To determine the orientation of the type I collagen, antibodies recognizing the Nterminal end of type I collagen were used. The antibodies to type I collagen after rotaryshadowing appear as globular structures with diameters of approximately 10 nm (Figure
3.5).
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3.3.4 Binding of rBSP on type I collagen
Our initial TEM studies of the rBSP-collagen interaction involved the use of the
in-house prepared collagen. A mixture consisting of rBSP (50 µg/ml) and type I collagen
(5 µg/ml) was incubated overnight at 4°C and rotary-shadowed with platinum. Analysis
of multiple TEM copper grids shows the mean rBSP binding site on type I collagen to be
31% of the total distance from one end of the collagen molecule with a standard deviation
of 5.58% (at the 95% confidence level) (Figure 3.6A). Subsequently, TEM studies of the
rBSP-collagen interaction with the collagen obtained from Sigma was completed and
based on the results of binding of both N-terminal collagen antibody and rBSP, it appears
rBSP binds closer to the N-terminal end (Figure 3.6B). Furthermore, this suggests that
BSP covers a region that is approximately 315±57 (at the 95% confidence level) residues
from the N-terminal end of the collagen molecule, corresponding to a region
encompassing residues 258 to 372. Figure 3.6B was not included in the determination of
the mean and standard deviation as the length of the C-terminus was not well-defined and
therefore a significant margin of error would result.
After analysis of all the TEM copper grids, it was evident the main difficulty was
locating monomeric type I collagen molecules with both rBSP and anti-type I collagen
antibody bound to it. In most instances, either unbound molecules (rBSP, anti-type I
collagen antibodies and type I collagen) or singly bound proteins were observed.
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Figure 3.3 Rotary-shadowing TEM of recombinant BSP.
rBSP (50 µg/ml) was visualized by (B) rotary-shadowing with platinum at an angle of 5°
and a single BSP molecule was selected for magnification (D). The buffer (70%
glycerol/30% 0.01 M ammonium formate) was rotary-shadowed and served as the control
(A). The schematic drawing [adapted from (9)] (C) illustrates the shape of rBSP particle
found in (B, D) and in the literature (9). Scale bar = 100 nm
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Figure 3.4 Rotary-shadowing TEM of type I collagen molecules.
Type I collagen (prepared in-house and from Sigma) was dissolved in 70% glycerol/30%
0.01M ammonium formate to a concentration of 5 µg/ml and rotary-shadowed. Both
preparations of type I collagen have the characteristic semi-flexible, rod-like structure of
monomeric type I collagen molecules (red rectangles). In addition, apparent type I
collagen aggregates are observed with the in-house prepared collagen. The samples were
analyzed in a Philips CM-10 TEM operating at 80 kV. Magnification 130,000 x. Scale
bar = 100 nm
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Figure 3.5 Rotary-shadowed N-terminal type I collagen antibodies with platinum.
Rotary-shadowed antibodies to type I collagen (5µg/ml) possess a globular appearance
with a diameter of approximately 10 nm. Representative anti-type I collagen antibodies
are indicated by purple arrows. Magnification 130,000 x. Scale bar = 100 nm
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Figure 3.6 Binding of rBSP on type I collagen.
rBSP (50 µg/ml) and type I collagen (prepared in-house; 5 µg/ml) were incubated
overnight at 4°C and rotary-shadowed with platinum (A). The binding location of rBSP
on type I collagen is indicated by the white arrows. In addition, TEM studies were
completed with the collagen obtained from Sigma and the binding of the N-terminal
collagen antibody (black arrow) and rBSP are indicated (white arrow) (B). The binding
location of rBSP on type I collagen is at a position of approximately 130 nm (white
arrow) from the N-terminal end of the collagen molecule. Measurements were made
using the ImageJ software. The total length of the individual collagen molecules and the
distance of the rBSP binding site measured from N-terminal end of the collagen
molecules are indicated. Magnification 130,000 x. Scale bar = 100 nm
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3.4

DISCUSSION
The aim of the present study was to gain insight into the BSP-type I collagen

interaction. We have previously determined that the BSP-type I collagen interaction is
mainly hydrophobic in nature, but stabilized by electrostatic forces. Additionally, the type
I collagen-binding region has been determined to be residues 18-45 on BSP, a highly
conserved region that is rich in hydrophobic and basic amino acids (11). However, the
BSP-binding region on type I collagen is unknown. In this study, using rotary-shadowing
TEM, the BSP-binding site was localized on type I collagen.
Rotary-shadowing TEM shows rBSP as a monomer with a globular structure that
is linked to an elongated thread-like structure, which is consistent with the findings of
Wuttke et al. Moreover, Wuttke et al., proposed the globular structure of rBSP, expressed
from human embryonic kidney (HEK 293) cells, to be the C-terminal region since it does
not contain any glycans. In contrast, the thread-like structure contains the highly
glycosylated structure located at residues 180-220 (9). However, with regards to the
prokaryotically-expressed rBSP used in our studies, the globular structure is likely due to
the high levels of hydrophobic residues, while the thread-like structure is likely due to the
high content of acidic amino acids (12).
Both types of collagen used in this study were extracted from rat tail tendons
which have been shown to be a good source of monomeric collagen. However, a small
content of covalently cross-linked polymeric collagen is likely to be present as crosslinking cannot be completely prevented or reversed (13). These cross-linked polymeric
collagen molecules were observed with the in-house prepared collagen. With regards to
the monomeric collagen molecules observed, the lengths of these molecules were
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consistent with the findings of Dahl et al., which found the mean length to be 250 nm and
standard deviation to be 48 (5). Unexpectedly, platinum-shadowed collagen molecules
from Sigma were lighter in colour than the platinum-shadowed collagen molecules
prepared in-house. This is likely due to a smaller amount of the contrast-enhancing metal
(platinum) being evaporated onto the protein surface which is believed to have occurred
during the processing of these samples in our studies (1-3).
The BSP-collagen interaction is only partly electrostatic and, in fact, it is mainly
hydrophobic in nature (11). These findings parallel those of Kasugai et al., which
determined that bone fragments demineralized with 4 M guanidine-HCl (a strong
dissociative denaturant) still contained native BSP bound to type I collagen (14, 15).
Therefore, it is postulated that BSP binds along the collagen molecule at a site with a
surface chemistry that is, at least in part, hydrophobic. Type I collagen has an isoelectric
point of 9.1 and a net charge of ~40+ at physiological pH. The molecule has a total of
270 basic residues (Arg, Lys, Hyl, and His) and 222 acidic residues (Asp and Glu).
However, there are three regions along the collagen molecule that contain areas of high
hydrophobicity. Two of the regions are in an overlap zone (c2-c1, which corresponds to
residues 213-248) and (a4-a3, residues 307-324), while one of the regions is in a gap
region (a1-e2, residues 342-374). Of relevance, Maitland et al., proposed that the
hydrophobic domains of NCPs are involved in binding to the hydrophobic domains of
type I collagen (16). Correlating these findings with the known triple-helical type I
collagen sequences, the BSP-binding region (residues 255 to 372) comprises two regions
along the collagen molecule that are high in hydrophobic amino acids, (a4-a3, a region
encompassing residues 307-324) and (a1-e2, residues 342-374).
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Using a far-Western blotting technique, Fujisawa et al., found that BSP bound to
the α2 chain of the collagen molecule. However, there are many potential issues with this
study including the non-specific binding to the α1 chain and that the collagen utilized in
this study was not in a triple-helical form (18). Previous work demonstrated that the
triple-helical structure of type I collagen is important for interacting with BSP and it is
likely that at least two of the α chains are involved (19). San Antonio et al., mapped the
binding sites of hundreds of type I collagen ligands onto a 2-D model of the fibril and the
distribution of the binding sites suggest these can be organized into two domains: the
“cell interaction domain” and the “matrix interaction domain”. The “cell interaction
domain” comprising an overlap region contains integrin-mediated cell-to-cell
interactions, while the “matrix interaction domain”, overlapping a gap region, contains
ECM interactions.
We have previously demonstrated that two glutamic acid-rich regions are
responsible for the nucleating activity, and this activity is increased 10-fold upon binding
to collagen. Studies on calcified turkey tendon and in bone have shown initial mineral
formation occurring in the gap regions of type I collagen (21-23). Moreover, Landis et
al., proposed that the packing of consecutive 2-D collagen arrays into 3-D assemblages
results in the formation of channels or gaps which are postulated to be the sites of
nucleation. Furthermore, given the pore space between adjacent type I collagen
molecules is 0.24 nm and the unstructured, flexible nature of BSP, it is postulated that the
glutamic-acid regions can extend into the gap region of the adjacent collagen molecule
and initiate mineral formation. Of relevance, DPP, a proposed mediator of mineralization

86

in dentin, has been shown to bind primarily to the fibril surface at the “e” band that is
present in the middle of a gap region (24).
In conclusion, our findings suggest that the N-terminal hydrophobic sequence
(residues 18-45) of BSP binds to collagen at a region that encompasses residues 258 to
372. This corresponds to BSP binding an overlap region of the collagen fibril by its Nterminal collagen-binding domain and the two glutamic acid rich regions binding in the
gap region of the adjacent collagen molecule where it initiates mineral formation (Figure
3.8)
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Figure 3.7 Schematic of the triple-helical type I collagen sequences of the BSP
binding site.
The BSP-binding region on type I collagen is approximately 315±60 residues from the Nterminal end of the collagen molecule, or residues 258 to 372. (A) Residues 255 to 342
(purple rectangle) lie in an overlap region while (B) residues 343 to 372 (orange
rectangle) lie in a gap region of the collagen fibril. The basic (Lys and Arg) and acidic
residues (Asp and Glu) are shown in bold. Regions with a high concentration of charged
residues are enclosed within rectangles and the letters correspond to the bands observed
after positive staining of the collagen fibril. [Adapted from (17)]

a2
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Figure 3.8 Model of BSP-mediated hydroxyapatite nucleation.
(A) BSP binds to type I collagen at a site that is approximately 31% from the N-terminal
end of the molecule. (B) This corresponds to BSP binding an overlap region of the
collagen fibril by its N-terminal collagen-binding domain (purple) and the two glutamic
acid rich regions (brown) binding in the gap region of the adjacent collagen molecule
where it initiates mineral formation.
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4.1

INTRODUCTION
The extracellular matrix (ECM) is a dynamic structure that constantly undergoes

changes in response to stimuli such as inflammation, wound healing and cancer (1).
There are many proteinases that mediate the degradation of the ECM including the matrix
metalloproteinase (MMP) family, the adamalysin-related membrane proteinases
(ADAMs) family and tissue serine proteinases such as thrombin (2).
Thrombin is a multifunctional protease that is important in a number of biological
processes such as blood coagulation and bone formation. The precursor of thrombin,
prothrombin, (also known as Factor II), is produced in the liver and secreted into the
blood circulation. Upon injury, prothrombin is converted to thrombin by the
prothrombinase complex for blood clot formation (3). The involvement of thrombin in
bone repair is primarily via the activation of protease-activated receptor 1 (PAR-1), a G
protein-coupled receptor expressed by osteoblasts, thereby mediating proliferation of
these cells (4). Thrombin also inhibits apoptosis of osteoblasts (5). In addition, thrombin
cleaves a number of ECM proteins such as osteopontin (OPN) (6) and bone sialoprotein
(BSP) (7).
Previous studies from our laboratory have shown that thrombin cleaves rat BSP at
Arg27-Tyr28, a site that is conserved in mouse, pig and human, but not in cow, which has
a thrombin-cleavage site at Arg122-Lys123 (7). Interestingly, thrombin cleaves rat BSP
in the middle of the collagen-binding domain (BSP18-45), which effectively abolishes
collagen-binding (unpublished data). The physiological relevance of this conserved
thrombin cleavage site, however, has not been fully elucidated and is the main focus of
this study.
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In addition to hydroxyapatite (HA) nucleation, acidic phosphoproteins of the
ECM also function as signaling molecules in physiological pathways (8, 9). BSP contains
a highly-conserved C-terminal RGD sequence that interacts with the αvβ3 integrin and has
been shown to be important in cell adhesion and migration of osteoblast and tumor cells
(8-12). In addition, BSP has been shown to promote angiogenesis by facilitating the
migration and attachment of human umbilical vein endothelial cells (13).
Since BSP has been shown to be a chemotactic agent, we hypothesize that, upon
bone injury, thrombin becomes activated, then cleaves and releases BSP into the ECM.
Subsequently, BSP can act as a signal molecule to recruit osteoprogenitor cells that will
differentiate into osteoblasts. The purpose of this study was to determine whether
thrombin cleaves and releases BSP from type I collagen. Thrombin-digestion reactions
were completed and analyzed using SDS-PAGE and staining with Stains-All and silver,
Western blotting and MALDI-MS.

4.2

MATERIALS AND METHODS

4.2.1 MATERIALS
Human alpha-thrombin was purchased from Haematologic Technologies Inc.
(Essex Junction, VT). Type I collagen was extracted from rat tail tendons in our
laboratory as previously described (14). Sprague-Dawley rats (250-300 g) were obtained
from Charles River Breeding Laboratories (Wilmington, MA). Amino-caproic acid,
benzamidine HCl, N-ethyl maleimide and phenylmethylsulfonyl fluoride (PMSF) and NTris(hydroxymethyl)methyl-2 aminoethanesulfonic acid (TES) were all purchased from
Sigma-Aldrich (St. Louis, MO).
For sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE),
ammonium persulfate (APS), N, N, N’, N’-tetramethylethane-1,2-diamine (TEMED),

96

acrylamide/bis-acryalmide, SDS and pre-stained protein standards were purchased from
Bio-Rad Laboratories (Hercules, CA). β-mercaptoethanol and glycine were obtained
from Thermo Fisher Scientific (Rockford, IL). Isopropanol was from VWR International
(West Chester, PA). Imidazole, Stains-All and silver nitrate were purchased from SigmaAldrich. Anti-BSP was purchased from abcam® (Toronto, Ontario). Hybond-P
polyvinylidene fluoride transfer (PVDF) membranes, enhanced chemiluminescence
(ECL) reagents, hyperfilm-ECL film and horseradish peroxidase (HRP)-conjugated antirabbit antibodies were obtained from GE Healthcare (Amersham).

4.2.2 METHODS
4.2.2.1 Thrombin cleavage of recombinant BSP (rBSP) bound to type I collagen
An overview of the thrombin-digestion experiments on rBSP bound to type I
collagen is illustrated in Figure 4.1. rBSP (10 µg) was incubated with either (1) type I
collagen fibrils or (2) soluble type I collagen that was subsequently allowed to form
fibrils. The two set-ups are described below.
a) Incubation of rBSP after collagen fibril formation
Type I collagen (4 mg/ml) fibril formation was induced with the addition of 250
µl TES-phosphate buffer (270 mM NaCl, 30 mM Na2HPO4 and 60 mM TES pH 7.5) at
37°C and incubated for 4 h. Subsequently, rBSP (10 µg) was added to the collagen fibrils
and incubated overnight at 4°C. This should result in rBSP binding to the surface of the
collagen fibrils.
b) Incubation of rBSP before collagen fibril formation
rBSP (10 µg) was incubated with soluble type I collagen (4 mg/ml) overnight at
4°C. Subsequently, fibril formation was induced with the addition of TES-phosphate
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buffer at 37°C for 4 h. This should result in some of the rBSP being internalized within
the collagen fibrils.
In both set-ups (a and b), unbound rBSP was first removed by buffer exchange
using Amicon® Ultra-0.5 centrifugal filter units. A total of five buffer exchanges were
performed. The BSP-collagen complexes were then incubated with thrombin (0.08 U) in
digestion buffer (50 mM Tris HCl, 10 mM CaCl2, and 1X PBS) at 22°C for 2 h. After
recovery of supernatant, the two different preparations of rBSP and type I collagen were
then incubated with 10% SDS at 22°C for 1 h to release any rBSP that was still
associated with the collagen fibrils. The recovered solutions were analyzed by 12% SDSPAGE gel and staining with Stains-All and silver as previously described (15) or loaded
onto a 6% SDS-PAGE gel and transferred onto a PVDF for western blot analysis. Briefly,
membranes were blocked with 5% milk powder in phosphate-buffered saline containing
Tween-20 (PBS-T) and incubated overnight at 4°C. The membranes were then incubated
with anti-BSP (1:500 dilution) for 1 h followed by incubation with anti-rabbit-HRP
antibodies (1:1000 dilution, GE Healthcare) for another hour. Four consecutive washes
(10 min) with PBS-T were completed between incubation steps. The membranes were
then developed with ECL reagents (5 min) and analyzed using the ChemiImager 5500 gel
doc system and corresponding software (Alpha Innotech).
4.2.2.2 Thrombin cleavage of native BSP (nBSP) and demineralized rat bone
fragments
Rat bone nBSP was extracted as previously described (16). nBSP (5 µg) was
incubated with thrombin (0.08 U) in thrombin-digestion buffer at 22°C for 2 h. The
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reaction solutions were then concentrated and loaded onto a 12% SDS-PAGE gel and
stained with Stains-All and silver for analysis (15).
To prepare demineralized bone chips for study of thrombin susceptibility, an
established bone extraction protocol was followed (16). Briefly, adult rat tibia, femur,
humerus, radius and ulna were excised and fragmented into large chunks with a hammer
and chisel. Subsequently, the bone fragments were further broken down with a mortar
and pestle under liquid nitrogen. The bone chips were then freeze-thawed with 1X PBS
containing proteinases inhibitor (PI; 100 mM amino-caproic acid, 5 mM benzamidine
HCl, 5 mM N-ethyl maleimide and 1 mM PMSF). This was repeated for a total of four
times. Bone chips were then incubated with chloroform: methanol (3:1) at 4°C for 2 h to
remove adipose tissue. 1X PBS (containing PI) was then used to remove the chloroform:
methanol. Subsequently, noncollagenous proteins were extracted from the chips using 4
M GuHCl/50 mM Tris buffer, pH 7.4, containing PI (1l a day per 100 g bone) for four
days. A 24-h wash with 1X PBS (exchanged three times) was then used to remove the 4
M GuHCl/Tris buffer. Following this, mineral-associated proteins were extracted using
0.5 M EDTA/ 50 mM Tris buffer, pH 7.4, containing PI (50 ml of EDTA solution per
gram of bone per day) for four days. After the removal of the EDTA extract solutions,
bone fragments were washed with 1X PBS for a total of three times.
The bone fragments (known to contain BSP bound to type I collagen) (17, 18)
were then incubated with various concentrations of thrombin (0.02 – 0.08 U) in
thrombin-digestion buffer at 22°C for 2 h. The reaction solutions were concentrated to 40
µl and loaded onto a 6% SDS-PAGE gel and transferred onto a PVDF membrane for
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western blot analysis as described earlier or loaded onto a 12% SDS-PAGE gel and
stained with Stains-All and silver (15).
4.2.2.3 Matrix-assisted laser desorption mass spectrometry (MALDI-MS) analysis
The collagenous residue of the demineralized rat bone fragments (after incubation
with thrombin) and non-digested nBSP were analyzed by MALDI-MS (Bruker® Reflex
IV, MALDI TOF MS, Department of Biochemistry, UWO). Sample aliquots of 2 µl were
mixed with 2 µl of sinapinic acid in 50 % methanol/0.5% trifluroacetic acid and spotted
onto a 96-well MALDI plate. The plate was analyzed using a Reflex IV MALDI-TOF
instrument in positive-ion mode. Mass spectra were collected and peaks were assigned
using the XTOF software (Bruker, Germany).
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Incubation of rBSP after

Incubation of rBSP before

collagen fibril formation

collagen fibril formation

Figure 4.1 An overview of the thrombin digestion experiments of rBSP bound to
type I collagen. rBSP (10 µg) was incubated with either type I collagen fibrils (left) or
soluble type I collagen (right) that was subsequently allowed to form fibrils. Prior to the
addition and incubation of thrombin, unbound rBSP was removed by buffer exchange.
The thrombin-digestion products were analyzed by Stains-All and silver.
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4.3

RESULTS

4.3.1 Thrombin cleavage of rBSP bound to type I collagen
The two different preparations of rBSP and type I collagen were incubated with
thrombin and the products were analyzed by Stains-All and silver staining and western
blot. To ensure that the rBSP detected was the result of thrombin cleavage and not
unbound rBSP, multiple washes were done using 1X PBS (prior to the incubation with
thrombin). The first and fifth washes were also loaded onto the gels (Figures 4.2A and
4.2B, W1 and W5).
A band of approximately 55 kDa is apparent in the first washes and after addition
and incubation with thrombin (Figures 4.2A and 4.2B, W1 and +thrombin lanes) from
both rBSP-collagen preparations. However, the intensity of the band in the +thrombin
lanes at 55 kDa from the rBSP incubated with fibrillar collagen is stronger than the
corresponding band recovered from the preparation of rBSP preincubated with
monomeric collagen prior to reconstitution (Figure 4.2A[a]). Following incubation with
thrombin, both rBSP-collagen preparations were incubated with 10% SDS to recover all
non-covalently bound protein. A band of approximately 55 kDa is apparent (Figure 4.2A,
+SDS lanes). This suggests that the rBSP detected after incubation with thrombin was
released from the surface of the (a) collagen fibrils or (b) within the collagen fibrils.
However, the intensity of the bands in (Figure 4.2B, rBSP only and + thrombin lanes) are
not expected based on the intensity of the bands in (Figure 4.2A, rBSP only and +
thrombin lanes), a possible explanation for this is that full-length rBSP reacts poorly
with anti-BSP.
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4.3.2 Analysis of nBSP and demineralized rat bone fragments for
thrombin susceptibility
nBSP was analyzed for thrombin susceptibility. Non-digested nBSP has an
apparent Mr of 80 kDa, whereas after incubation with thrombin a second band at
approximately 60 kDa is apparent (Figure 4.3A, +thrombin).
Rat bone fragments that were first demineralized were also analyzed for thrombin
susceptibility and release of BSP. The collagenous residue after EDTA was incubated
with various concentrations of thrombin (0.02 – 0.08 U) in thrombin-digestion buffer at
22°C for 2 h and the products were analyzed by SDS-PAGE and stained with Stains-All
and silver and western blotting. From the western blot analysis, solutions recovered from
incubated bone chips without thrombin contained BSP-immunoreactive bands with
apparent molecular weights of 180, 80 and 60 kDa (Figure 4.3C, -thrombin lane).
Addition of increasing amounts of thrombin resulted in a corresponding increased
recovery of bands at 180, 80 and 60 kDa and evidence of lower-molecular-weight
peptides (Figure 4.3C, +thrombin lanes). It is believed that the slower-migrating protein
(180 kDa) represents polymers of BSP. Stains-All and silver staining of the recovered
proteins after thrombin incubation shows a mixture of proteins with a prominent band at
approximately 60 kDa (Figure 4.3B, +thrombin lane).

4.3.3 Matrix-assisted laser desorption mass spectrometry (MALDI-MS)
analysis
The thrombin-digested reactions of the demineralized rat bone fragments and
controls containing no thrombin were analyzed by MALDI-MS. The non-digested rat
native BSP (control) gave rise to a peak at 52,423 m/z (Figure 4.4A) whereas the
thrombin-digested rat native BSP gave rise to a peak at approximately 47,500 m/z
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resulting in a loss of approximately 5000 m/z. Thrombin gave rise to a peak at 36,708
m/z. MALDI-MS analysis of the thrombin-digested demineralized bone fragments
reveals a major peak at 43,784 m/z and minor peaks at 34,112 m/z, 28,069 m/z, 22,025
m/z and 13,727 m/z (Figure 4.4D). This is not consistent with the western blot analysis
(Figure 4.3A), suggesting that non-BSP proteins in the sample were identified by MS.
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A

B

Figure 4.2 Analysis of thrombin-digestion reactions of rBSP bound to type I
collagen.
Prior to the addition and incubation with thrombin, unbound rBSP from the two different
rBSP-collagen preparations - (a) rBSP on the surface of collagen fibrils and (b) some
rBSP internalized within the collagen fibrils - was removed with a total of five buffer
exchanges using 1X PBS. Following this, (a) and (b) were incubated with 10% SDS. The
products (the first and fifth washes, incubation with thrombin and 10% SDS) were
collected and loaded onto a (A) 12% SDS-PAGE gel and stained with Stains-All and
silver for analysis or (B) loaded onto a 6% SDS-PAGE gel and transferred onto a PVDF
membrane and incubated with anti-BSP antibodies to probe for BSP. A band
corresponding to the release of rBSP from type I collagen fibrils is apparent at 55 kDa
[W1, +thrombin and +SDS lanes in (a) and (b)]. “M” is the molecular marker.
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B

C

Figure 4.3 Analysis of nBSP and demineralized rat bone fragments for thrombin
susceptibility.
nBSP was incubated with thrombin and the reactions were concentrated and loaded onto
a (A) 12% SDS-PAGE gel and stained with Stains-All and silver for analysis.
Additionally, rat bone fragments that were first demineralized with EDTA was incubated
with various concentrations of thrombin in digestion buffer at 22°C for 2 h. The reactions
were loaded onto a (B) 12% SDS-PAGE gel and stained with Stains-all and silver for
analysis or loaded onto a (C) 6% SDS-PAGE gel and transferred onto a PVDF membrane
and incubated with anti-BSP antibodies to probe for BSP. Bands corresponding to the
release of nBSP (C; red box) were present when incubated at all concentrations of
thrombin. “M” is the molecular marker.

106

A

B
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D

Figure 4.4 MS analysis of thrombin-digested demineralized bone chips
(A) Mass spectrum of non-digested rat BSP with a dominant peak at 52,423 m/z.
(B) Mass spectrum of thrombin-digested rat BSP with a dominant peak at approximately
47,500 m/z.
(C) Mass spectrum of thrombin with a dominant peak at 36,708 m/z.
(D) Mass spectrum of thrombin-digested rat bone showing a dominant peak at 43,784
m/z and minor peaks at 34,112 m/z, 28,069 m/z, 22,025 m/z and 13,727 m/z.
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4.4

DISCUSSION
Bone formation and remodeling are complex, yet still poorly understood,

processes that involve many factors. The acidic phosphoproteins of the ECM have been
shown to function as signaling molecules in physiological pathways. The aim of the
present study was to gain insight into the conserved thrombin-cleavage site of BSP.
Previous studies from our laboratory have shown that thrombin cleaves rat BSP at Arg27Tyr28. In this study, we present evidence that rBSP bound to type I collagen and
demineralized rat bone fragments (containing nBSP bound to type I collagen) are
susceptible to thrombin cleavage. This was confirmed with Stains-All and silver, western
blot and MALDI-MS analysis.
nBSP was analyzed for thrombin susceptibility. A 60-kDa band was apparent
after incubation with thrombin. This was not expected based on the thrombin-cleavage
site at Arg27-Tyr28. Previous unpublished data from our laboratory show non-digested
rBSP with a peak at ~34,754 (m/z), while the thrombin-digested rBSP had a peak at
~30,761 (m/z), resulting in a loss of approximately 4,000 m/z. Therefore, the expected
BSP fragment would be approximately 4 kDa less than the full-length and this loss may
not be evident on SDS-PAGE. This shortened BSP fragment at 60 kDa was also evident
in the western blot analysis of demineralized rat bone fragments which is likely due to the
slow migration of BSP. Moreover, the additional bands below 60 kDa are possibly
proteolytic fragments of BSP while the high-molecular-weight bands may be a result of
transglutaminase, a protein-crosslinking enzyme that generates polymers of BSP (19).
This observation of a shortened BSP fragment at 60 kDa is consistent with the findings of
Gorski et al., where proteolytic fragments of BSP (45-50 kDa) were found in bone
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mineralization foci (BMF). Moreover, in the presence of a serine protease inhibitor 4-(2Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF), cleavage of BSP was
inhibited. This suggests the BSP fragments were a result of serine protease activity,
which thrombin is a serine protease (20).
The MS peak at 52,423 m/z for the non-digested BSP (control) coincides with the
findings of Zaia et al. (21) and Wuttke et al. (22). However, the dominant MS peak at
43,784 m/z for thrombin-digested bone was not expected based on the thrombincleavage site at Arg27-Tyr28. The expected peak for the demineralized rat bone
fragments (after incubation with thrombin) would be closer to 47,500 m/z based on the
thrombin-digested BSP. Since the Stains-All and silver staining of the demineralized rat
bone fragments showed a mixture of proteins, this suggests the unexpected MS peak is
not likely BSP. Although MS has been demonstrated to be a good tool in proteomic
analysis, the highly acidic nature of BSP appears to be a problem for detection by MS.
Previous studies from our laboratory have shown that a chondroitin sulfate proteoglycan,
with a highly acidic protein core, was not detectable by MS (unpublished data). A
potential explanation for this is that the less-negatively charged proteins in the sample
mixture are more easily protonated and detected by MS than BSP.
For proteins to become functional, often proteolysis is required. Also, processing
of protein through proteolysis could potentially modulate its functional roles. Many
polypeptides isolated from bone and dentin have been shown to be distinct proteolyticderived large peptides. In some instances, it has been demonstrated that these cleavages
are necessary for protein function. Dentin sialophosphoprotein (DSPP) the inactive
precursor, is cleaved by PHEX, resulting in two active fragments, dentin sialoprotein
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(DSP) and dentin phosphophoryn (DPP) (23). Similarly, dentin matrix protein 1 (DMP-1)
exists as 37-kDa and 57-kDa peptides and it has been proposed that this cleavage is
important in osteogenesis and dentinogenesis (24). Of relevance, thrombin also cleaves
OPN at a Gly-Arg-Gly-Asp-Ser (GRGDS) site into an N-terminal and a C-terminal
fragment. Many studies have analyzed the physiological relevance of this cleavage.
Grassinger et al., demonstrated that the N-terminal thrombin-cleaved OPN fragment acts
as a chemotactic agent for hemopoietic stem and progenitor cells via α9β1 and α4β1
integrins (25). Similarly, thrombin-cleaved OPN fragments have been shown to induce
migration of a variety of cell types including monocytes, macrophages, neutrophils and
lymphocytes (26-29).
There are several physiological processes that require the migration of
osteoprogenitor cells. During the normal processes of bone remodeling and bone repair,
there is a recruitment of osteoprogenitor cells responsible for generating mature bone.
Although there are numerous factors within bone that can stimulate cell migration such as
cytokines, the restricted expression of BSP to cells of osteogenic origin suggests BSP
may act as an ECM signal. Moreover, BSP has been shown to act as a chemotactic agent
for osteoblast and cancer cells through the activation of the focal adhesion kinase (FAK)
and extracellular signal-regulated kinase (ERK) signaling pathway (8-12, 30). FAK is a
tyrosine kinase that is activated when it is phosphorylated at Tyr397 (31). Following, FAK
associates with various SH2/SH3 domain-containing proteins including Src and Grb2
(32). This results in the activation of the mitogen-activated protein kinase (MAPK)
pathway, such as ERK via the GTPase such as Ras (33). ERK has been demonstrated to
be important in cell migration through the activation of downstream targets such as
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members of the activator protein-1 (AP-1) (34). BSP has been demonstrated to influence
osteoblast differentiation (10) through the activation of osteoblast-related transcription
factors including Runx2 (35), alkaline phosphatase and Osx (36).
In the present study, we demonstrated that BSP bound to type I collagen is
susceptible to thrombin cleavage. We speculate that BSP released from bone by
thrombin may function as a chemotactic agent in bone repair. In order to evaluate this
hypothesis, we will have to determine whether intact and/or degraded BSP is released
from the mineralized collagenous matrix after injury and whether thrombin-cleaved BSP
from collagen can mediate osteoblast differentiation. The results from these studies will
provide further insight into the physiological significance of this cleavage.
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5.1

SUMMARY
Biomineralization is a complex, yet poorly understood, process that involves

many factors. The precise mechanisms of crystal nucleation and growth are unknown.
The highly organized arrangement of hydroxyapatite (HA) within the collagen matrix
suggests that mineralization in bone is a tightly regulated process. Furthermore,
dysregulation results in pathological conditions such as osteogenesis imperfecta. In
normal calcified bone, the HA crystals tend to be plate-like (with average dimensions of
~45 nm in length, ~25 nm in width and 3-6 nm thick) and are aligned parallel to one
another and with their long axes parallel to the collagen fibrils (1, 2). In contrast, the HA
crystals in pathologically calcified tissues, may be thick, bulky blocks or narrow spearshaped structures with dimensions that are three-to ten-fold larger than normal HA
crystals (3), or may be similar in shape (plate-like) to normal crystals, but thinner (4).
Additionally, the abnormal HA crystals are not aligned with respect to the long axis of
the collagen fibrils (3, 4). Irregularities in the collagen matrix, where the overlap and gap
regions are mismatched, is proposed to be responsible for the various sizes and shapes of
HA crystals found in pathological calcified tissues.
While there are several postulated mechanism for biomineralization, one
prominent mechanism requires preexistence of a surface such as type I collagen for ion
deposition and nucleation by acidic proteins (5-7). The collagen matrix neither promotes
nor inhibits HA nucleation, however; an acidic phosphoprotein of the ECM is proposed
to be play this role. Bone sialoprotein (BSP) is a likely candidate due to its spatiotemporal pattern of expression and HA-nucleating capabilities (8-10). Moreover, since
this nucleation activity is increased upon binding to collagen, it is postulated that BSP is
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secreted into the ECM by osteoblasts, binds to type I collagen in the gap regions (where
initial mineral formation is seen to occur), or the regions adjacent to it, and mediates
mineral formation.
Previous work demonstrated that the BSP-collagen interaction is mainly
hydrophobic in nature, but stabilized by electrostatic forces. The collagen-binding region
has been located to a region spanning residues 18-45 on BSP, a highly conserved region
that is rich in hydrophobic and basic amino acids (11). The BSP-collagen interaction
requires a native triple-helical type I collagen structure, but does not require either
collagen telopeptides or fibrils (12). Furthermore, post-translational modifications
(PTMs) are not involved in collagen-binding since both rat-bone-extracted BSP and
recombinant BSP (rBSP; unmodified BSP) demonstrate comparable binding affinities.
Although much research has been devoted to studying the BSP-collagen interaction, the
BSP-binding region on type I collagen has not been identified and was the main focus of
this thesis.
In chapter two, a chemical cross-linking method was initially used to determine
the BSP-interacting domain on type I collagen. These experiments involved the
incubation and conjugation of single-cysteine rBSP (1-100) mutants to the sulfhydryl
reactive, photoactivable cross-linkers APB and APDP. Type I collagen was then added
and irradiated with UV light to induce cross-link formation. Multiple approaches and
modifications were taken in an effort to improve the efficiency and/or recovery of BSPcollagen cross-linked products. However, the yield of the cross-linked products was low
in all instances and therefore the complexes were not further characterized. It is still a
puzzle as to why the chemical cross-linkers did not result in sufficient cross-linked
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products, as both cross-linkers have been used successfully in many cross-linking
experiments studying protein-protein interactions. A possible explanation lies in the
cross-linkers’ spacer arms; perhaps these were not long enough to reach a collagen amino
acid from the cysteine residue of the single-cysteine rBSP (1-100) peptide. Unfortunately,
these two cross-linkers possess the longest spacer arms among commercially available
heterobifunctional cysteine-reactive cross-linkers with a photoactivable group. Another
potential explanation is that the current method of detection was not sufficiently sensitive
to detect the BSP-collagen cross-linked products. Therefore, due to these difficulties in
obtaining sufficient BSP-collagen cross-linked products, an alternative protocol using
rotary-shadowing TEM was used.
Rotary-shadowing TEM has been utilized extensively for identifying the binding
site(s) of various proteins on collagen as it offers high-contrast visualization of individual
macromolecules. In chapter three, this method was used to visualize the BSP-interacting
domain on collagen. This involved rotary-shadowing with platinum full-length
prokaryotically expressed rBSP, type I collagen (extracted from rat tail tendons) and an
anti-type I collagen antibody recognizing the N-terminal end of collagen molecules.
Rotary-shadowing TEM shows rBSP as a monomer possessing a globular structure of
~10 nm linked to an elongated thread-like structure of ~25 nm, while type I collagen
appeared as semi-flexible molecules. These structures are consistent with the findings in
the literature (13, 14). The locus of interaction is approximately 31% from the N-terminus
based on studies in which BSP, type I collagen and an antibody recognizing the Nterminal end of the collagen molecule were combined. Taking this into consideration, as
well as the arrangement of the collagen fibril, the highly flexible structure of BSP and the
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hydrophobic nature of the BSP-collagen interaction, I postulate that the N-terminal
hydrophobic sequence (residues 18-45) of BSP binds collagen in an overlap region at a
site that is rich in hydrophobic residues, while one or both of the glutamic acid-rich
regions extend into the gap region of the adjacent collagen molecule.
In addition to HA nucleation, BSP has been demonstrated to function as a
signaling molecule. BSP contains a highly conserved C-terminal RGD site that interacts
with the αvβ3 integrin and has been shown to be important in osteoprogenitor cell
migration and differentiation (15-17). Within the collagen-binding domain of BSP, there
is a highly conserved thrombin cleavage site at Arg27-Tyr28. Thrombin cleaves rat BSP
in the middle of the collagen-binding domain (residues 18-45), which effectively
abolishes collagen binding, implying physiological significance. To address the relevance
of this, analysis of the products of the incubation of thrombin with rBSP bound to fibrillar
collagen and with demineralized bone chips was completed. Analysis with SDS-PAGE
and western blotting demonstrated that rBSP bound to type I collagen fibrils is
susceptible to thrombin cleavage allowing for its release from the collagen complex.
Similarly, endogenous BSP present in demineralized bone chips is also released from
these chips with thrombin incubation. Since BSP has been shown to function as a
chemotactic agent, I hypothesize that, upon bone injury, thrombin becomes activated,
cleaves and releases BSP into the ECM. Subsequently, BSP can act as a signal molecule
to recruit osteoprogenitor cells which will differentiate into osteoblasts.
Conclusions and Future Directions
The first objective of this thesis was to ultimately map the BSP-binding region on
type I collagen down to the amino-acid level. As the present studies provide qualitative
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insight into the BSP-binding domain on collagen, future studies will be important to fully
elucidate this domain and to determine how this interaction promotes nucleation of HA.
Future TEM studies to validate the BSP-binding domain on collagen could involve the
use of the biotinylated rBSP (18-45) peptide present in the laboratory. This approach is
promising since a shorter peptide than the rBSP (1-100) peptide may reduce the inherent
variability noted in the site of interaction with the larger peptide. Furthermore, because
of the strong binding affinity of avidin to biotin and the relatively large mass of avidin,
the site of interaction should be readily apparent. In addition, synthetic triple-helical type
I collagen peptides can be synthesized and utilized in solid-binding assays to further
characterize the BSP-binding region. Researchers have extensively used synthetic triplehelical peptides of type II and III collagen to map protein- or peptide-binding locations
(18). Moreover, the BSP-binding site on collagen determined in this present study can be
used as constraints in molecular-modeling techniques to generate a predicted structure
(19, 20). Additionally, structural studies such as 1H NMR, CD and X-ray scattering may
be used to determine change in BSP conformation, if any, upon binding to collagen (21).
The findings of the second objective suggest that the release of BSP from bone
may provide signals to initiate the bone repair process. In order to evaluate this
hypothesis, it is important to determine whether full-length and/or degraded BSP is
released from the mineralized collagenous matrix after injury and whether thrombincleaved BSP from collagen can mediate osteoblast differentiation. Although MS has been
demonstrated to be a good tool in proteomic analysis, the highly acidic nature of BSP
may pose a problem. In the present study, the thrombin-digested BSP in the
demineralized bone mixtrue was not detectable by MS. A potential explanation is that in
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a mixture of proteins, the less-acidic proteins are more easily protonated and detected by
MS. Thus, additional purification and concentration of the acidic peptides prior to
analysis by MS should be included, similar to what was done for the analysis of the
highly phosphorylated osteopontin (22).The results from these studies will provide
further insight into the physiological significance of this cleavage.
In cases where the injury is so severe that natural healing cannot take place, the
use of biomaterials may aid the healing process. These materials can be classified into
three groups (1) osteoinductive, (2) osteoconductive, and (3) calcigenic materials (23).
Established osteoinductive materials, such as BMP, are involved in the recruitment and
differentiation of osteoprogenitor cells into osteoblasts (24). However, disadvantages of
BMP are the cost and the potential for serious side effects. While BSP has apparent
osteoinductive properties in vitro, studies in vivo are not yet conclusive.
Osteoconductive materials such as HA composites provide a scaffold upon which bone
can form. However, these materials can result in disorganized mineralization of bone
tissues (24). Finally, calcigenic materials are involved in inducing local calcification
rather than bone formation, which would allow the bone defect itself to be stabilized and
potentially repaired more rapidly. This involves a calcigenic agent binding to a collagen
scaffold in order to produce a mineralized matrix that is biologically and structurally
comparable to bone (25). A postulated calcigenic agent is BSP.
In conclusion, the findings from these studies have added novel information to the
BSP-collagen interaction and its role in bone formation and mineralization. This may
ultimately lead to the generation of therapeutic agents to promote bone repair.

123

5.2

REFERENCES

1. Robinson, R.A. (1952) An electron-microscopic study of the crystalline inorganic
component of bone and its relationship to the organic matrix. J. Bone Joint Surg. Am. 34,
389-476
2. Weiner, S., and Price, P.A. (1986) Disaggregation of bone into crystals. Calcif. Tissue
Int. 39, 365-375
3. Landis, W. (1995) The strength of a calcified tissue depends in part on the molecular
structure and organization of its constituent mineral crystals in their organic matrix. Bone
16, 533-544
4. Fratzl, P., Paris, O., Klaushofer, K., and Landis, W. (1996) Bone mineralization in an
osteogenesis imperfecta mouse model studied by small-angle x-ray scattering. J. Clin.
Invest. 97, 396
5. Glimcher, M.J. (1987) The nature of the mineral component of bone and the
mechanism of calcification. Instr. Course Lect. 36, 49
6. Hunter, G.K., Nyburg, S.C., and Pritzker, K.P. (1986) Hydroxyapatite formation in
collagen, gelatin, and agarose gels. Coll. Relat. Res. 6, 229-238
7. Veis, A., and Perry, A. (1967) The Phosphoprotein of the Dentin Matrix. Biochemistry
(N.Y.). 6, 2409-2416
8. Gorski, J.P. (1992) Acidic phosphoproteins from bone matrix: a structural
rationalization of their role in biomineralization. Calcif. Tissue Int. 50, 391-396
9. Glimcher, M.J. (1989) Mechanism of calcification: Role of collagen fibrils and
collagen‐phosphoprotein complexes in vitro and in vivo. Anat. Rec. 224, 139-153
10. Hunter, G.K., and Goldberg, H.A. (1993) Nucleation of hydroxyapatite by bone
sialoprotein. Proc. Natl. Acad. Sci. 90, 8562-8565

124

11. Tye, C.E., Hunter, G.K., and Goldberg, H.A. (2005) Identification of the type I
collagen-binding domain of bone sialoprotein and characterization of the mechanism of
interaction. J. Biol. Chem. 280, 13487-13492
12. Baht, G.S., Hunter, G.K., and Goldberg, H.A. (2008) Bone sialoprotein-collagen
interaction promotes hydroxyapatite nucleation. Matrix Biol. 27, 600-608
13. Wuttke, M., Muller, S., Nitsche, D.P., Paulsson, M., Hanisch, F.G., and Maurer, P.
(2001) Structural characterization of human recombinant and bone-derived bone
sialoprotein. Functional implications for cell attachment and hydroxyapatite binding. J.
Biol. Chem. 276, 36839-36848
14. Hall, C.E. (1956) Visualization of individual macromolecules with the electron
microscope. Proc. Natl. Acad. Sci. 42, 801
15. Gordon, J.A., Hunter, G.K., and Goldberg, H.A. (2009) Activation of the mitogenactivated protein kinase pathway by bone sialoprotein regulates osteoblast differentiation.
Cells Tissues Organs 189, 138-143
16. Gordon, J.A., Sodek, J., Hunter, G.K., and Goldberg, H.A. (2009) Bone sialoprotein
stimulates focal adhesion-related signaling pathways: role in migration and survival of
breast and prostate cancer cells. J. Cell. Biochem. 107, 1118-1128
17. Gordon, J.A., Tye, C.E., Sampaio, A.V., Underhill, T.M., Hunter, G.K., and
Goldberg, H.A. (2007) Bone sialoprotein expression enhances osteoblast differentiation
and matrix mineralization in vitro. Bone 41, 462-473
18. Farndale, R.W., Lisman, T., Bihan, D., Hamaia, S., Smerling, C.S., Pugh, N.,
Konitsiotis, A., Leitinger, B., de Groot, P.G., Jarvis, G.E., and Raynal, N. (2008) Cellcollagen interactions: the use of peptide Toolkits to investigate collagen-receptor
interactions. Biochem. Soc. Trans. 36, 241-250
19. Mouradov, D., King, G., Ross, I.L., Forwood, J.K., Hume, D.A., Sinz, A., Martin,
J.L., Kobe, B., and Huber, T. (2008) Protein structure determination using a combination

125

of cross-linking, mass spectrometry, and molecular modeling. Methods Mol. Biol. 426,
459-474
20. Back, J.W., de Jong, L., Muijsers, A.O., and de Koster, C.G. (2003) Chemical crosslinking and mass spectrometry for protein structural modeling. J. Mol. Biol. 331, 303-313
21. Russell, R.B., Alber, F., Aloy, P., Davis, F.P., Korkin, D., Pichaud, M., Topf, M., and
Sali, A. (2004) A structural perspective on protein–protein interactions. Curr. Opin.
Struct. Biol. 14, 313-324
22. Zhang, H., Hunter, G.K., Goldberg, H.A., Lajoie, G.A., and Yeung, K.K. (2007) An
integrated procedure of selective injection, sample stacking and fractionation of
phosphopeptides for MALDI MS analysis. Anal. Chim. Acta. 581, 268-280
23. Boden, S.D. (2005) The ABCs of BMPs. Orthop. Nurs. 24, 49-52
24. Samartzis, D., Khanna, N., Shen, F.H., and An, H.S. (2005) Update on Bone
Morphogenetic Proteins and Their Application in Spine Surgery. J Am. Coll. Surg. 200,
236-248
25. Hunter, G.K., Poitras, M.S., Underhill, T.M., Grynpas, M.D., and Goldberg, H.A.
(2001) Induction of collagen mineralization by a bone sialoprotein–decorin chimeric
protein. J. Biomed. Mater. Res. 55, 496-502

126

Rose Yee
CURRICULUM VITAE
EDUCATION
Master of Science (MSc.) Candidate
University of Western Ontario, London ON

September 2011

Bachelor of Science with Honours, B.Sc. (Hons)
McMaster University, Hamilton, ON

September 2007 - 2011

RELATED WORK EXPERIENCE
Undergraduate Teaching Assistant
University of Western Ontario, London ON

January 2011 - April 2011

b2

a1

b1

e2

a4

a3

a2

